Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 2124. Отображено 100.
02-05-2013 дата публикации

COSMETIC FOAM

Номер: US20130108557A1
Автор: Abram Albert Zorko, Goldstein Iulian
Принадлежит:

The present invention provides aerosol foams comprising Aloe vera. In particular, the foams comprise (a) Aloe vera, (b) a surfactant and (c) a propellant. The foams may further comprise one or more of the group consisting of an α-hydroxy acid, a β-hydroxy acid, a humectant, a thickening agent, a dermatologically acceptable excipient, and mixtures thereof. 123-. (canceled)24. A topical aerosol foam composition comprising: (a) Aloe vera , (b) a surfactant and (c) a hydrocarbon propellant , and (d) a keratolytic agent.25. The composition according to claim 24 , wherein the Aloe vera is Aloe barbadensis leaf juice.26. The composition according to claim 24 , wherein the Aloe vera is Aloe vera gel concentrate and the composition further comprises water in an amount from about 40% to about 95% by weight.27. The composition according to claim 26 , wherein the composition comprises water in an amount from about 70% to about 95% by weight.28. The composition according to claim 24 , wherein the surfactant is a non-ionic surfactant.29. The composition according to claim 28 , wherein the non-ionic surfactant is an ethoxylated alcohol.30. The composition according to claim 29 , wherein the ethoxylated alcohol is selected from the group consisting of ceteareth-6 claim 29 , ceteareth-12 claim 29 , ceteareth-20 claim 29 , ceteareth-25 claim 29 , ceteth-10 claim 29 , ceteth-20 claim 29 , laureth-4 claim 29 , laureth-5 claim 29 , laureth-9 claim 29 , laureth-10 claim 29 , laureth-12 claim 29 , laureth-15 claim 29 , laureth-20 claim 29 , laureth-23 claim 29 , oleth-10 claim 29 , oleth-20 claim 29 , steareth-10 claim 29 , steareth-20 and steareth-100 claim 29 , and mixtures thereof31. The composition according to claim 30 , wherein the ethoxylated alcohol is ceteareth-20.32. The composition according to claim 24 , wherein the hydrocarbon propellant is a mixture of propane claim 24 , n-butane claim 24 , and isobutane.33. The composition according to 24 claim 24 , further comprising a ...

Подробнее
Номер записи: 1
02-05-2013 дата публикации

Coated effervescent tablet

Номер: US20130108745A1
Автор: Bjoern Skjaevestad, Robert Wahren
Принадлежит: DELANTE HEALTH AS

A dietary tablet having a core containing a microencapsulated oil part and an effervescent agent, a coat which isolates the core from the environment and protects the core from oxidation and at least one ingredient giving taste. Suitable oils are preferably chosen from oils rich in polyunsaturated fatty acids, especially omega-3 and omega-6 fatty acids. The tablet is intended to be administered without water and to disintegrate in the oral cavity.

Подробнее
Номер записи: 2
09-05-2013 дата публикации

INTRAORALLY DISINTEGRATING TABLET

Номер: US20130115287A1
Автор: Nakamura Kazuhiro, Ogawa Teppei
Принадлежит: TEIJIN PHARMA LIMITED

Disclosed is an orally disintegrating tablet which masks bitterness, dissolves well, and which permanently retains good oral disintegration properties immediately following manufacture. The disclosed orally disintegrating tablet is formed by compression-molding an organic acid together with particles comprising active ingredient-containing nuclear particles covered by a layer containing water-insoluble polymers and/or enteric polymers. 1. An intraorally disintegrating tablet , in which an active ingredient-containing core particle coated with a layer comprising a water insoluble polymer and/or an enteric polymer has been compression molded together with an organic acid.2. The tablet of claim 1 , wherein the content of the organic acid is 1 to 10 wt %.3. The tablet of claim 1 , wherein the organic acid is ascorbic acids and/or citric acids.4. The tablet of claim 1 , wherein the water insoluble polymer and/or the enteric polymer is a methacrylic acid copolymer.5. The tablet of claim 1 , wherein the water insoluble polymer and/or the enteric polymer is ethyl cellulose.6. An intraorally disintegrating tablet claim 1 , in which an active ingredient-containing core particle coated with a layer containing a water insoluble polymer and/or an enteric polymer and a granule obtained by coating a disintegrant-containing particle with a disintegrant have been compression molded together with an organic acid. The present invention relates to an intraorally disintegrating tablet comprising an organic acid as a disintegration accelerator.Intraorally disintegrating tablets containing organic acids such as ascorbic acids and citric acids are known. Specific examples thereof include, those containing ascorbic acid as an active ingredient (Patent Documents 1-3) and those illustrating the addition of an organic acid as a dissolution agent for an active ingredient in order to ensure absorptivity (Patent Documents 4 and 5). However, none of the above documents describe or suggest ...

Подробнее
Номер записи: 3
23-05-2013 дата публикации

PREPARATIONS OF EFFERVESCENT FORMULATIONS COMPRISING SECOND AND THIRD GENERATION CEPHALOSPORIN AND USES THEREOF

Номер: US20130129791A1
Автор: Bilgic Mahmut
Принадлежит:

The invention relates to effervescent pharmaceutical dosage forms including cefdinir as the active agent, and their preparation. The invention also relates to effervescent formulations including ceftibuten and/or its pharmaceutically acceptable salts, hydrates, solvates, esters, amorphous and crystal forms and/or a combination thereof. The invention also relates to pharmaceutical compositions including (Z)-3-Carboxymethyl-7-(2-(2-furyl)-2-methoxyiminoacetylamino)-3-sefem-4-carboxylic acid which is named cefuroxime axetil or any pharmaceutically acceptable derivative thereof, and the use of these compositions in the treatment of bacterial infections. Lastly, the invention relates to pharmaceutical formulations including a third generation cephalosporin together with clavulanic acid and/or derivatives thereof as the active agents. 1. A pharmaceutical formulation formulated in effervescent form comprising cefdinir as the active agent characterized in that two different taste regulating agents are used and the ratio of the first taste regulating agent having 31-90% (w/w) water solubility at 25° C. and the second taste regulating agent having 5-30% (w/w) water solubility at 25° C. is in the range of 5:1 and 1:1.2. (canceled)3. The pharmaceutical formulation according to claim 1 , wherein the first taste regulating agent used in effervescent formulations of the present invention is selected from a group comprising dextrose claim 1 , fructose claim 1 , glucose claim 1 , lactitol claim 1 , maltitol claim 1 , maltose claim 1 , sorbitol claim 1 , saccharine sodium claim 1 , sodium cyclamate claim 1 , sodium chloride claim 1 , potassium chloride claim 1 , sucrose and xylitol or combinations thereof.4. The pharmaceutical formulation according to claim 3 , wherein sodium chloride is used as the first taste regulating agent.5. The pharmaceutical formulation according to claim 1 , wherein the second taste regulating agent used in effervescent formulations of the present invention ...

Подробнее
Номер записи: 4
06-06-2013 дата публикации

AMPHIPATHIC LIPID-BASED SUSTAINED RELEASE COMPOSITIONS

Номер: US20130142876A1
Автор: Howard Scott A., Purvis Troy
Принадлежит: PEGASUS LABORATORIES, INC.

Chewable sustained release compositions and their methods of production are provided. The sustained release compositions contain amphipathic lipids, which are used to encapsulate various drugs and active ingredients. 1. A composition comprising:(a) about 0.5 to about 90 weight percent of one or more active ingredients;(b) between about 0.5 to about 80 weight percent of one or more amphipathic lipids; and(c) between about 5 to about 90 weight percent of at least one bulking or spheronizing agent,wherein said at least one active ingredient being encapsulated within a matrix comprising said one or more amphipathic lipids and said at least one bulking or spheronizing agent,wherein said composition exhibits an in vitro dissolution rate of said active ingredients as measured by a USP Dissolution Apparatus II of about 10% to 50% after about 2 hours, about 25% to 90% after about 4 hours, more than about 60% after about 12 hours, and more than about 75% after about 16 hours.2. The composition according to wherein said composition comprises at least about 1 and/or no more than about 60 weight percent of said one or more active ingredients.3. The composition according to wherein said composition comprises at least about 1 and no more than about 50 weight percent of said one or more amphipathic lipids.4. The composition according to wherein said composition comprises at least about 10 and no more than about 70 weight percent of said at least one bulking or spheronizing agent.5. The composition according to wherein said composition exhibits an in vitro dissolution rate of said active ingredients as measured by a USP Dissolution Apparatus II of no more than 90% of said active ingredients released after 8 hours.6. The composition according to wherein said one or more amphipathic lipids are selected from the group consisting of phospholipids claim 1 , lecithins claim 1 , ceramides claim 1 , sphingolipids claim 1 , steroids claim 1 , and glycolipids.7. The composition according to ...

Подробнее
Номер записи: 5
20-06-2013 дата публикации

Composition of Antigen and Method of Sublingual Administration

Номер: US20130156812A1
Автор: Hauer Stephen, Holm Kristin
Принадлежит:

A method of sublingually administering an effective amount of an antigenic composition to a mammal in order to produce a mucosal and systemic immune response. 1. A method for the sublingual administration of a therapeutic compound to a human or animal comprising mixing an effective amount of said therapeutic compound with a pharmaceutically acceptable viscous compound and providing said mixture to said human or animal for oral consumption.2. A method according to wherein said viscous compound is spread on a serving structure such that full oral consumption by said human or animal requires repeated licking of said mixture.3. A method according to wherein said viscous compound is spread inside a serving structure such that full oral consumption by said human or animal requires repeated licking of said mixture.4. A method according to wherein said animal is a dog.5. A method according to wherein said animal is a cat.6. A method according to wherein the viscous compound is flavored to appeal to a human or animal.7. A method according to wherein said therapeutic compound contains allergenic extracts.8. A method according to wherein the viscous compound additionally contains any of a prebiotic agent and a probiotic agent.9. A method according to wherein said viscous carrier is paste.10. A method according to wherein said viscous carrier is a gel.11. A method according to wherein said composition is in the form of an aqueous solution.12. A composition comprising:a. one or more antigenic extracts; andb. a viscous compound.13. A composition according to wherein said viscous compound is a paste claim 11 , gelatin claim 11 , gum claim 11 , or cellulosic compound.14. A composition according to wherein said viscous compound is peanut butter.15. A composition according to wherein said composition additionally comprises a prebiotic.16. A composition according to wherein said composition additionally comprises a probiotic. Allergic disease is an increasingly prevalent health ...

Подробнее
Номер записи: 6
27-06-2013 дата публикации

Production method and effervescent formulations comprising cephalosporin and clavulanic acid

Номер: US20130164227A1
Автор: Mahmut Bilgic
Принадлежит: Individual

The present invention relates to the process for the preparation of the pharmaceutical formulations comprising a cephalosporin antibiotic and clavulanic acid or any pharmaceutically acceptable derivative thereof. The present invention also relates to processes for preparation of said formulations and their use in bacterial infections.

Подробнее
Номер записи: 7
27-06-2013 дата публикации

FORMULATIONS FOR OSTEOPOROSIS

Номер: US20130164342A1
Автор: Bilgic Mahmut
Принадлежит:

The present invention relates to effervescent formulations comprising genistein with an average particle size (d) in the range of to μm as active agent. The present invention also relates to pharmaceutical formulations with high bioavailability comprising calcium, genistein and vitamin D in order to be used in prophylaxis and treatment of osteoporosis and related diseases. 1. A formulation comprising calcium , vitamin D , and genistein characterized in that said formulation is in effervescent form.2. The effervescent formulation according to claim 1 , characterized in that said formulation is formulated in powder claim 1 , granule claim 1 , pellet claim 1 , micro tablet or tablet form.3. The effervescent formulation according to claim 2 , characterized in that said formulation is formulated in tablet form.4. The effervescent formulation according to claim 1 , characterized in that calcium comprised in said formulation is in salt form.5. The effervescent formulation according to claim 4 , characterized in that calcium comprised in said formulation is in carbonate claim 4 , chloride claim 4 , phosphate claim 4 , citrate claim 4 , lactate claim 4 , glubionate claim 4 , gluceptate claim 4 , or gluconate salt form.6. The effervescent formulation according to claim 5 , characterized in that calcium salt comprised in said formulation is calcium carbonate.7. The effervescent formulation according to claim 1 , characterized in that said formulation comprises 5-60% calcium or calcium salt by weight.8. (canceled)9. The effervescent formulation according to claim 1 , characterized in that the particle size of calcium or calcium salt is smaller than 100 μm.10. The effervescent formulation according to claim 9 , characterized in that the particle size of calcium or calcium salt is smaller than 60 μm.11. The effervescent formulation according to claim 1 , characterized in that vitamin D is vitamin D(ergocalciferol) claim 1 , vitamin D(cholecalciferol) claim 1 , or a combination ...

Подробнее
Номер записи: 8
04-07-2013 дата публикации

SOFT FOOD COMPOSITION WITH PROBIOTICS AND PREBIOTICS FOR MASKING MEDICATIONS

Номер: US20130171204A1
Автор: DuBourdieu Daniel J., Gor Tapan A., Lall Rajiv, Raval Devraj C., Sinha Anita K.
Принадлежит: VETS PLUS, INC.

A soft extruded food composition containing probiotics, enzymes, and vitamins for wrapping medications, such as pills or tablets, for animal consumption. The flavor of the wrapped solid medication is masked by the food composition and thus becomes more palatable to the animal while providing additional health benefits in the form of probiotics, prebiotics, enzymes, and vitamins. 1. A consumable composition for providing health benefits to an animal comprising: a carrier base comprising components selected from the group consisting of a powder, an emulsifier, a starch, an oil, a softening agent, and water in a combination and in amounts effective to confer viscoelasticity to the viscoelastic mass; and', 'an effector component selected from the group consisting of a probiotic, a prebiotic, and an enzyme selected from the group consisting of a carbohydrase, a lipase, and a protease., 'a viscoelastic mass comprising2Aspergillus, Trichoderma, Bacillus, Bacteriodies, Bifidobacterium, Lactobacillus, Leuconostoc, Streptococcus, Pediococcus, Propionibacterium, Saccharomyces, Enterococcus, Escherichia. The composition of comprising the probiotic claim 1 , wherein the probiotic is a microorganism in a genus selected from the group consisting of claim 1 , and combinations thereof.3. The composition of comprising the probiotic in an amount of from about 0.01 to about 1×10CFU/g of the viscoelastic mass.4. The composition of comprising the prebiotic claim 1 , wherein the prebiotic is selected from the group consisting of inulin claim 1 , lactulose claim 1 , lactitol claim 1 , a fructooligosaccharide claim 1 , a galactooligosaccharide claim 1 , a xylooligosaccharide claim 1 , an isomaltooligosaccharide claim 1 , a mannaoligosaccharide claim 1 , a lactosucrose claim 1 , a cereal fiber claim 1 , a soy oligosaccharide claim 1 , raffinose claim 1 , beet pulp claim 1 , psyllium claim 1 , cellulose claim 1 , gum arabic claim 1 , and combinations thereof.5. The composition of comprising ...

Подробнее
Номер записи: 9
11-07-2013 дата публикации

ORAL FILM-FORM BASE AND PREPARATION

Номер: US20130177605A1
Автор: ASARI Daisuke, HORI Mitsuhiko, SHISHIDO Takuya
Принадлежит: NITTO DENKO CORPORATION

The present invention provides an oral film-form base which has a rapid dissolution profile in the mouth and sufficient film strength, and gives an improved taking property by foaming in the mouth. The oral film-form base includes an edible polymer soluble both in water and in an organic solvent having a solubility parameter of 9.7 or higher, a foaming agent, and an auxiliary foaming agent, wherein the foaming agent is foamable in the presence of water, and the foaming agent and the auxiliary foaming agent each are insoluble in the organic solvent, have an average particle size of 0.1 to 60 μm, and are included in particle states. 1. An oral film-form base comprisingan edible polymer soluble both in water and in an organic solvent having a solubility parameter of 9.7 or higher,a foaming agent, andan auxiliary foaming agent,wherein the foaming agent is foamable in the presence of water, andthe foaming agent and the auxiliary foaming agent each are insoluble in the organic solvent, have an average particle size of 0.1 to 60 μm, and are included in particle states.2. The oral film-form base according to claim 1 ,wherein the foaming agent and the auxiliary foaming agent each have an average particle size of 0.1 μm to 30 μm.3. The oral film-form base according to claim 1 ,wherein the edible polymer is polyvinylpyrrolidone and/or hydroxypropyl cellulose.4. The oral film-form base according to claim 3 ,wherein the polyvinylpyrrolidone has a weight-average molecular weight of 2,500 to 3,000,000.5. The oral film-form base according to claim 3 ,wherein the hydroxypropyl cellulose has a weight-average molecular weight of 10,000 to 1,200,000.6. The oral film-form base according to claim 3 ,wherein the hydroxypropyl cellulose has a hydroxypropoxy substitution degree of 50 to 100%.7. The oral film-form base according to claim 1 ,wherein the foaming agent is at least one selected from the group consisting of sodium hydrogen carbonate, sodium carbonate, magnesium carbonate, ...

Подробнее
Номер записи: 10
18-07-2013 дата публикации

BODY CAVITY FOAMS

Номер: US20130183250A1
Автор: Besonov Alex, Eini Meir, Friedman Doron, Tamarkin Dov
Принадлежит: Foamix Ltd.

The invention relates to an alcohol-free cosmetic or therapeutic foam carrier comprising water, a hydrophobic organic carrier, a foam adjuvant agent, a surface-active agent and a gelling agent. The cosmetic or therapeutic foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable for inclusion of both water-soluble and oil soluble therapeutic and cosmetic agents. 2. The foamable composition of claim 1 , wherein the carrier further comprises an active agent.3. The foamable composition of claim 1 , wherein the liquefied or compressed gas propellant is present at about 3% to about 25% by weight of the carrier.4. The foamable composition of claim 1 , wherein the organic solvent is selected from the group consisting of an emollient claim 1 , a polar solvent claim 1 , an essential oil claim 1 , and mixtures of any two or more thereof.5. The foamable composition of claim 1 , wherein the carrier comprises a micro-emulsion.6. The foamable composition of claim 1 , wherein the carrier comprises nano-particles.7. The foamable composition of claim 1 , wherein the surface-active agent is present at less than about 2% by weight of the carrier.8. The foamable composition of claim 1 , wherein the polymeric agent is present at less than about 1% by weight of the carrier.9. The foamable composition of claim 1 , wherein the carrier does not include petrolatum.10. The foamable composition of claim 2 , wherein the active agent is selected from the group consisting of an antibacterial agent claim 2 , an antibiotic claim 2 , an anti-parasitic agent claim 2 , an antifungal agent claim 2 , an antiviral agent claim 2 , a corticosteroid claim 2 , a steroidal anti-inflammatory agent claim 2 , a non-steroidal immunomodulating agent claim 2 , an immunosuppressant claim 2 , an anti-allergic agent claim 2 , an antihistamine claim 2 , an anticancer agent claim 2 , a hormone claim 2 , an androgen claim 2 , an estrogen claim 2 , ...

Подробнее
Номер записи: 11
25-07-2013 дата публикации

ORAL PRODUCT

Номер: US20130189333A1
Автор: Atchley Frank Scott, DiNovi Christopher Joseph, Gao Feng, Gee Diane, Griscik Gregory, Hulan Phillip M., Kobal Gerd
Принадлежит: ALTRIA CLIENT SERVICES INC.

An oral product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix, cellulosic fibers embedded in the mouth-stable polymer matrix, and an additive dispersed in the mouth-stable polymer matrix. The oral product is adapted to release the additive from the body when the body is received within the oral cavity and exposed to saliva. 1. An oral product , comprising a body that is wholly receivable in an oral cavity , the body comprising:a mouth-stable polymer matrix;cellulosic fibers embedded in the mouth-stable polymer matrix; andan additive dispersed in the mouth-stable polymer matrix such that the additive is released from the body when the body is received within the oral cavity and exposed to saliva.2. The oral product of claim 1 , wherein the mouth-stable polymer matrix comprises polyurethane.3. The oral product of claim 1 , wherein the mouth-stable polymer matrix comprises polyester.4. The oral product of claim 1 , wherein the mouth-stable polymer matrix comprises polyacrylate.5. The oral product of claim 1 , wherein the mouth-stable polymer matrix comprises apolyethylene claim 1 , SEBS claim 1 , SBS claim 1 , or another thermal plastic elastomer.6. The oral product of claim 1 , further comprising a plasticizer dispersed in the mouth-stable polymer matrix.7. The oral product of claim 6 , wherein the plasticizer is selected from the group consisting of propylene glycol claim 6 , glycerin claim 6 , vegetable oil claim 6 , triglycerides claim 6 , and combinations thereof.8. The oral product of claim 1 , further comprising a sweetener dispersed in the body.9. The oral product of claim 1 , wherein the sweetener is selected from the group consisting of saccharine claim 1 , sucralose claim 1 , aspartame claim 1 , acesulfame potassium claim 1 , and combinations thereof.10. The oral product of claim 1 , wherein the additive is selected from the group consisting of minerals claim 1 , vitamins claim 1 , dietary ...

Подробнее
Номер записи: 12
01-08-2013 дата публикации

Non-Starch Based Soft Chewables

Номер: US20130197006A1
Автор: HAMANN Hans-Juergen, KANIKANTI Venkata-Rangarao
Принадлежит: Bayer Animal Health GmbH

The present invention generally relates to soft chewables, especially suitable for delivering active ingredients to animals and processes for the preparation thereof. In various embodiments, the soft chewable comprises a pharmaceutically effective amount of at least one active ingredient, a flavoring agent, a disintegrant a humectant, an antioxidant, a preservative, and water. In accordance with preferred embodiments, the soft chewable is essentially free of starch, oil glycols, waxes, and soy products. 1. A soft chewable comprising:(a) a pharmaceutical effective amount of at least one active ingredient;(b) a flavoring agent;(c) a disintegrant;(d) a humectant;(e) a binder(f) an antioxidant;(g) optionally a preservative; and(h) water.2. The soft chewable of comprising (g) a preservative.3. The soft chewable of wherein the soft chewable disintegrates in less than about 25 minutes as determined in accordance with method 2.9.1 (Test B) of the European Pharmacopoeia 6.0.43. The soft chewable of claim to wherein the disintegrant constitutes at least about 10 wt % claim 2 , at least about 12 wt % claim 2 , at least about 15 wt % claim 2 , at least about 17 wt % claim 2 , at least about 20 wt % claim 2 , at least about 25 wt % claim 2 , at least about 30 wt %. claim 2 , at least about 40 wt % claim 2 , or at least about 50 wt % of the soft chewable.5. The soft chewable of wherein the disintegrant is selected from the group consisting of carmellose calcium claim 4 , directly compressible mannitol claim 4 , crosslinked povidone claim 4 , polyvinyl sodium claim 4 , a mixture of directly compressible mannitol and polyvinyl sodium claim 4 , and combinations thereof.6. The soft chewable of wherein the disintegrant is selected from the group consisting of a mixture of polyvinyl sodium and directly compressible mannitol claim 4 , a mixture of polyvinyl sodium and polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer claim 4 , a mixture of croscarmellose sodium ...

Подробнее
Номер записи: 13
08-08-2013 дата публикации

L-ornidazole formulations and their applications in treatment of parasitic infections

Номер: US20130202698A1
Автор: Cang Zhang, Xiaoxin Tao, Yong Wang
Принадлежит: Nanjing Sanhome Pharmaceutical Co Ltd

This invention relates to new methods of treating parasitic infections, such as trichomonas vaginalis infection and cecum amoeba infection, using L-enantiomer enriched ornidazole, in particular enantiomerically pure L-ornidazole, which provides benefits such as higher efficacy and lower toxicity to central nervous system over the existing racemic Ornidazole drug. New methods of synthesizing L- and D-enantiomers of Ornidazole in high purity and enantiomeric excess (ee), new formulations of the enantiomerically enriched L- or D-ornidazole, as well as their preparation processes and methods of use, are also disclosed.

Подробнее
Номер записи: 14
08-08-2013 дата публикации

Phosphate binder formulation for simple dosing

Номер: US20130202699A1
Автор: Astrid Oppermann, Eva Fries-Schaffner, Friedrich Schulze, Johannes Bartholomaeus, Kai Strothmann
Принадлежит: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH

The invention relates to a pharmaceutical composition in the form of pourable granules or a chewable tablet containing at least one phosphate binding substance and at least one effervescent agent. The composition may be taken orally without adding water.

Подробнее
Номер записи: 15
29-08-2013 дата публикации

EFFERVESCENT NUTRITIONAL AND/OR DIETARY SUPPLEMENT COMPOSITION

Номер: US20130224304A1
Автор: Opheim Joar
Принадлежит: Nordic Naturals, Inc.

An effervescent composition is provided comprising a dry, free-flowing powder comprising (a) microcapsules comprising a hollow, solid, water soluble outer shell comprising a starch, a sugar or mixtures thereof and an inner core comprising a liquid, water immiscible oil comprising at least one polyunsaturated fatty acid, at least one derivative of a polyunsaturated fatty acid or mixtures thereof, and (b) an effervescing agent. 1. An effervescent composition comprising a dry , free-flowing powder comprising (a) microcapsules comprising a hollow , solid , water soluble outer shell comprising a starch , a sugar or mixtures thereof and an inner core comprising a liquid , water immiscible oil comprising at least one polyunsaturated fatty acid , at least one derivative of a polyunsaturated fatty acid or mixtures thereof , and (b) an effervescing agent.2. The effervescent composition of wherein the composition is selected from the group consisting of a dietary supplement claim 1 , nutritional supplement claim 1 , nutraceutical claim 1 , medicinal formulation or combinations thereof.3. The effervescent composition of wherein the starch comprises sodium octenyl succinate.4. The effervescent composition of wherein the sugar comprises glucose syrup.5. The effervescent composition of wherein the liquid claim 1 , water immiscible oil comprises a marine oil.6. The effervescent composition of wherein the marine oil comprises fish oil.7. The effervescent composition of wherein the liquid claim 1 , water immiscible oil comprises at least one omega-3 polyunsaturated fatty acid claim 1 , at least one derivative of an omega-3 polyunsaturated fatty acid claim 1 , or mixtures thereof.8. The effervescent composition of wherein the liquid claim 7 , water immiscible oil comprises ethyl esters of omega-3 polyunsaturated fatty acids.9. The effervescent composition of wherein the liquid claim 7 , water immiscible oil comprises glycerides of omega-3 polyunsaturated fatty acids.10. The ...

Подробнее
Номер записи: 16
12-09-2013 дата публикации

Pharmaceutical Compositions Comprising Terbinafine

Номер: US20130236514A1
Автор: BONNY Jean-Daniel, EUGSTER Andreas Carl, GUITARD Patrice, Hirsch Stefan
Принадлежит: NOVARTIS AG

This invention provides a terbinafine pharmaceutical composition which is emulsifable or self-emulsifying or in form of an emulsion wherein the composition is adapted for oral administration. 1. An oral terbinafine pharmaceutical composition which is emulsifiable or self-emulsifying or in the form of an emulsion , wherein said composition comprises a lipid component that is a triglyceride of CG-12 saturated fatty acids , a surfactant and an emulsion stabilizing agent that is a mixture of sodium carboxymethylcellulose and microcrystalline cellulose.2. A pharmaceutical composition according to wherein the lipophilic component is present in an amount of 15 to 25% by weight based on total weight of composition.3. A pharmaceutical composition according to wherein the surfactant is a phospholipid.4. A pharmaceutical composition according to wherein the surfactant is present in an amount of 1.5 to 5% by weight based on total weight of composition.5. A pharmaceutical composition according to further comprising water.6. A pharmaceutical composition according to wherein the mean droplet size of lipophilic phase is of about 0.1 to 30 IJm.7. A method for the treatment of fungal infections of the human body comprising administering a pharmaceutically effective amount of a pharmaceutical composition according to to a subject in need of such treatment. The present invention relates to a pharmaceutical composition comprising terbinafine.Terbinafine may be used e.g. in free form or in acid addition salt form. An acid addition salt form may be prepared from the free base form in conventional manner and vice-versa. Examples of suitable acid addition salt form are the hydrochloride, the lactate and the ascorbate. The free base and the hydrochloride are preferred.Terbinafine is known from e.g. BE-PS-853976 and EP-A-24587. It belongs to the class of allylamine anti-mycotics. It is acknowledged in the art and is commercially available under the trade name Lamisil®.Terbinafine is highly ...

Подробнее
Номер записи: 17
26-09-2013 дата публикации

ORAMUCOSAL PHARMACEUTICAL DOSAGE FORM

Номер: US20130252916A1
Автор: Danckwerts Michael Paul, Patel Rupal, Pillay Viness
Принадлежит: University of the Witwatersrand, Johannesburg

This invention relates to an oramucosal pharmaceutical dosage form in the form of a wafer. The wafer comprises a porous, hydroscopic, muco-adhesive polymeric matrix with at least one desired pharmaceutically active compound added thereto. The polymer is selected from a number of polymers having different dissolution rates and, in use when taken orally, the matrix adheres to an oramucosal surface to dissolve over a predetermined period of time to release the pharmaceutically active compound. The invention also extends to a method of manufacturing an oramucosal pharmaceutical dosage form in the form of a wafer which involves freeze drying or lyophilisation. 157-. (canceled)58. An oramucosal pharmaceutical dosage form comprising a porous , hydroscopic , muco-adhesive polymeric matrix comprising hydroxypropyl cellulose; excipients mannitol , lactose and glycine; and having at least one pharmaceutically active compound added thereto , the dosage form formulated into a wafer , in use the dosage form disintegrates within 30 seconds.59. The oramucosal pharmaceutical dosage form as claimed in claim 58 , wherein the pharmaceutically active compound is selected from the group consisting of: analgesics claim 58 , sedatives claim 58 , antihistamines and paediatric drugs.60. The oramucosal pharmaceutical dosage form as claimed in claim 59 , wherein the pharmaceutically active compound is an analgesic selected from the group consisting of: diclophenac claim 59 , aspirin and paracetamol.61. The oramucosal pharmaceutical dosage from as claimed in claim 59 , wherein the pharmaceutically active compound is a sedative selected from the group consisting of: diazepam claim 59 , zolpidem and zopiclone.62. The oramucosal pharmaceutical dosage form as claimed in claim 59 , wherein the pharmaceutically active compound is an antihistamine selected from the group consisting of: loratidine and chlorpheniramine.63. The oramucosal pharmaceutical dosage form as claimed in claim 59 , wherein the ...

Подробнее
Номер записи: 18
03-10-2013 дата публикации

AMPHIPATHIC LIPID-BASED SUSTAINED RELEASE COMPOSITIONS

Номер: US20130259937A1
Автор: Howard Scott A., Purvis Troy
Принадлежит:

Chewable sustained release compositions and their methods of production are provided. The sustained release compositions contain amphipathic lipids and matrix-forming polymers, which are used to encapsulate various drugs and active ingredients. The chewable sustained release compositions can maintain their sustained release properties even after being fragmented into a plurality of pieces. 1. A composition comprising:(a) one or more active ingredients;(b) one or more amphipathic lipids; and(c) at least one bulking or spheronizing agent,wherein said active ingredients being encapsulated within a matrix comprising said amphipathic lipids,wherein said composition exhibits an in vitro dissolution rate of said active ingredients as measured by a USP Dissolution Apparatus II of about 10% to 50% after about 2 hours, about 25% to 90% after about 4 hours, more than about 60% after about 12 hours, and more than about 75% after about 16 hours,wherein the average in vitro dissolution rate of said composition as measured by a USP Dissolution Apparatus II does not increase by more than 100% during the first 2 hours after said composition has been fragmented into two or more pieces.2. The composition according to wherein the average in vitro dissolution rate of said composition as measured by a USP Dissolution Apparatus II does not increase by more than 50% during the first 2 hours after said composition has been fragmented into two or more pieces.3. The composition according to wherein said composition comprises a plasticized matrix-forming polymer claim 1 , wherein said matrix encapsulating said active ingredients comprises said matrix-forming polymer.4. The composition according to wherein said matrix-forming polymer has a glass transition temperature (“Tg”) of not more than about 120° C.5. The composition according to wherein said matrix-forming polymer comprises a bulking or spheronizing agent claim 3 , a binder claim 3 , a flavoring agent claim 3 , a sustained coating ...

Подробнее
Номер записи: 19
03-10-2013 дата публикации

Ibuprofen Solid Oral Dosage Composition Comprising a Methacrylic Acid Copolymer

Номер: US20130261188A1
Автор: DAS ADITYA R., HIBI TORU
Принадлежит: TEIKOKU PHARMA USA, INC.

Aspects of the invention include organoleptically acceptable solid oral dosage compositions of ibuprofen. Solid oral dosage compositions according to certain embodiments include ibuprofen and a methacrylic acid copolymer in an amount sufficient to make the composition organoleptically acceptable for administering in an oral cavity of a subject to deliver ibuprofen to the subject. Methods for preparing and using solid oral dosage compositions of the invention are also described. 1. A solid oral dosage composition comprising:ibuprofen; anda methacrylic acid copolymer in an amount sufficient to make the solid oral dosage composition organoleptically acceptable for administering in an oral cavity of a subject.34-. (canceled)5. The solid oral dosage composition according to claim 1 , wherein the amount of ibuprofen in the solid oral dosage composition ranges from 20 mg to 200 mg.67-. (canceled)8. The solid oral dosage composition according to claim 1 , wherein the amount of methacrylic acid copolymer ranges from 40 mg to 400 mg.9. (canceled)10. The solid oral dosage composition according to claim 1 , wherein the solid oral dosage composition is formulated for maintaining in an oral cavity of a subject for a predetermined amount of time to deliver ibuprofen to the subject.11. The solid oral dosage composition according to claim 10 , wherein the solid oral dosage composition is formulated to be maintained in the oral cavity of a subject for 10 minutes or more.12. (canceled)13. The solid oral dosage composition according to claim 10 , wherein the solid oral dosage composition is formulated to be disintegrated in the oral cavity by chewing.14. The solid oral dosage composition according to claim 10 , wherein the solid oral dosage composition is formulated to be dissolved in the oral cavity.15. The solid oral dosage composition according to claim 1 , wherein the solid oral dosage composition further comprises a souring agent.16. The solid oral dosage composition according to ...

Подробнее
Номер записи: 20
17-10-2013 дата публикации

NOVEL FUNCTIONAL FOOD PRODUCT AND METHOD THEREOF

Номер: US20130274339A1
Автор: LURYA Leonid, NOVODVORETS Vadim
Принадлежит:

A whole impregnated freeze dried food product for delivering a material of interest comprising; 2. The method according to claim 1 , wherein said step of drying the obtained food product is performed at a temperature of about 40° C.-about 60° C. under normal pressure or under vacuum.3. The method according to claim 1 , wherein said step of freeze drying said fresh food product is performed by combining vacuum process to said food product to remove moisture content.4. The method according to claim 1 , wherein said incubation in step iii is performed under vacuum.5. The method according to claim 1 , further comprising the step of drying the soaked food product;6. The method according to claim 1 , wherein said food product is dehydrated in step (b) until the residual moisture extent is between about 0% to about 5%.7. The method according to claim 1 , wherein said residual moisture extent is selected from a group consisting of: about 0% claim 1 , about 1% claim 1 , about 2% claim 1 , about 3% claim 1 , about 4% claim 1 , about 5% of said food product volume.8. The method according to claim 1 , wherein at least one of the following is true;a. said material of interest is a natural pharmacological or bio-active material containing a definite tasteb. said material of interest includes any of phytochemicals or nutraceutical material, said nutraceutical material selected from a group consisting of; vitamins, minerals, isoflavoronals, lycopene, resveratol, indocarbonals, anthocyanins, soluble fiber, high protein rice, and soy isolate or any combination thereofc. said food product further comprises food additives selected from a group consisting of acids, acidity regulators, anticaking agents, antifoaming agents, antioxidants, bulking agents, food coloring, color retention agents, emulsifiers, flavors, flavor enhancers, flour treatment agents, glazing agents, humectants, tracer gas, stabilizers, preservatives, sweeteners, thickenersd. said taste additives are volatile ...

Подробнее
Номер записи: 21
17-10-2013 дата публикации

ORALLY DISINTEGRATING TABLET

Номер: US20130274348A1
Автор: Kigoshi Makoto, Morita Hideki, Ota Motohiro, SATO Takafumi
Принадлежит: KYOWA HAKKO KIRIN CO., LTD.

It is an object of the present invention to provide an orally disintegrating tablet that has desirable oral disintegrability and excellent tablet hardness, a process for producing the same, and the like.

Подробнее
Номер записи: 22
24-10-2013 дата публикации

Immediate Release Pharmaceutical Compositions with Abuse Deterrent Properties

Номер: US20130280176A1
Автор: Diezi Thomas A., Park Jae Han, Raman Siva N.
Принадлежит: Mallinckrodt LLC

The present disclosure provides pharmaceutical compositions and processes for making solid dosage form pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties. The pharmaceutical compositions provided herein comprise at least one pharmaceutically active ingredient, at least one low molecular weight water-soluble polymer, at least one polyglycol, at least one polysaccharide, at least one clay mineral, and, optionally, an effervescent system. 1. A pharmaceutical composition comprising at least one active pharmaceutical ingredient (API) or a pharmaceutically acceptable salt thereof , at least one low molecular weight water-soluble polymer , at least one polyglycol , at least one polysaccharide , at least one clay mineral , and , optionally , an effervescent system.2. The pharmaceutical composition of claim 1 , wherein the low molecular weight water-soluble polymer has a molecular weight of no more than about 300 claim 1 ,000 daltons; the low molecular weight water-soluble polymer is chosen from a polyalkylene oxide claim 1 , a cellulose ether claim 1 , a polyolefinic alcohol claim 1 , a polyvinyl lactam claim 1 , a polycarboxylic acid claim 1 , and combinations thereof; and the low molecular weight water-soluble polymer is present in an amount from about 5% to about 60% by weight of the pharmaceutical composition.3. The pharmaceutical composition of claim 1 , wherein the polyglycol is chosen from a copolymer of ethylene glycol and propylene glycol claim 1 , a polyethylene glycol claim 1 , a polypropylene glycol claim 1 , and combinations thereof; and the polyglycol is present in an amount from about 5% to about 50% by weight of the pharmaceutical composition.4. The pharmaceutical composition of claim 1 , wherein the polysaccharide is a gum chosen from xanthan gum claim 1 , acacia gum claim 1 , diutan gum claim 1 , gellan gum claim 1 , guar gum claim 1 , fenugreek gum claim 1 , locust bean gum claim 1 , ...

Подробнее
Номер записи: 23
24-10-2013 дата публикации

Immediate Release, Abuse Deterrent Pharmaceutical Compositions

Номер: US20130280177A1
Автор: Diezi Thomas A., Herman Clifford J., Park Jae Han, Raman Siva N.
Принадлежит: Mallinckrodt LLC

The present disclosure provides pharmaceutical compositions and processes for making solid dosage form pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties. The pharmaceutical compositions provided herein comprise at least one pharmaceutically active ingredient, at least one low molecular weight hydrophilic polymer, at least one high molecular weight hydrophilic polymer, and an effervescent system. 1. A pharmaceutical composition comprising at least one active pharmaceutical ingredient (API) or a pharmaceutically acceptable salt thereof , at least one low molecular weight hydrophilic polymer , at least one high molecular weight hydrophilic polymer , and an effervescent system.2. The pharmaceutical composition of claim 1 , wherein the low molecular weight hydrophilic polymer has an average molecular weight of no more than about 200 claim 1 ,000 Daltons; the low molecular weight hydrophilic polymer is chosen from a polyalkylene oxide claim 1 , a cellulose ether claim 1 , a polyalkylene glycol claim 1 , a Poloxamer claim 1 , and combinations thereof; and the low molecular weight hydrophilic polymer is present in an amount from about 5% to about 50% by weight of the pharmaceutical composition.3. The pharmaceutical composition of claim 1 , wherein the high molecular weight hydrophilic polymer has an average molecular weight of at least about 400 claim 1 ,000 Daltons; the high molecular weight hydrophilic polymer is chosen from a polyalkylene oxide claim 1 , a cellulose ether claim 1 , a polysaccharide claim 1 , and combinations thereof; and the high molecular weight hydrophilic polymer is present in an amount from about 0.1% to about 30% by weight of the pharmaceutical composition.4. The pharmaceutical composition of claim 1 , wherein the effervescent system comprises an a) acid component chosen from an organic acid claim 1 , an inorganic acid claim 1 , and combinations thereof and b) a base component chosen ...

Подробнее
Номер записи: 24
31-10-2013 дата публикации

STABLE EFFERVESCENT BISPHOSPHONATE FORMULATIONS WITH RAPID SOLUBILIZATION CHARACTERISTICS

Номер: US20130287706A1
Автор: Hayward Marshall A., Schmidt Timo
Принадлежит: EFFRX PHARMACEUTICALS SA

A stable effervescent tablet, granule or powder composition free from excipients that may react with an effervescing organic acid component, comprising, an effective amount of a bisphosphonate bone resorption inhibitor, an effervescing organic acid component, an effervescing base component; wherein said composition is free of polyol binders and tableting lubricants; has a loss on drying of 0.25% (m/m) or less; has a complete disintegration time of no more than 180 seconds when placed in 3 to 8 fluid ounces of water at between 5-20° C.; and said bisphosphonate is incorporated as a micronized particle or by spray drying and is completely solubdised in water within 2 minutes without stirring. 1. A stable effervescent tablet , granule or powder composition free from excipients that may react with an effervescing organic acid component , comprising:an effective amount of a bisphosphonate bone resorption inhibitor,an effervescing organic acid component,an effervescing base component;wherein said composition is free of polyol binders and tableting lubricants; has a loss on drying of 025% (m/m) or less; has a complete disintegration time of no more than 180 seconds when placed in 3 to 8 fluid ounces of water at between 5-20° C.; and said bisphosphonate is incorporated as a micronized particle or by spray drying and is completely solubilised in water within 2 minutes without stirring.2. The composition of claim 1 , which been tableted and has a tablet hardness of 35 to 120 Newtons.3. The composition of . having tablet hardnesses in the range of 60 to 90 Newtons.4. The composition of claim 1 , having a disintegration time between 60 and 130 seconds.5. The composition of claim 1 , wherein the effervescing organic acid component contains 20-70% monosodium citrate.6. The composition of claim 1 , wherein the effervescing organic acid component contains 30-60% monosodium citrate.7. The composition of claim 1 , wherein the effervescing organic acid component contains 40- 50% ...

Подробнее
Номер записи: 25
07-11-2013 дата публикации

FLASHMELT ORAL DOSAGE FORMULATION

Номер: US20130296337A1
Автор: Desai Divyakant S., Kothari Sanjeev H.
Принадлежит:

There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients such as sweetening and flavoring agents. The subject granules are advantageous in that they are stable and can be prepared without the aid of solvents and without the need for special environments or handling. Dosage forms, especially tablets, prepared therefrom on conventional equipment disintegrate in the mouth in under about twenty five seconds. 1. A flash-melt pharmaceutical dosage form comprising a medicament , a superdisintegrant , a dispersing agent and a binder wherein said medicament is aripiprazole and wherein said dispersing agent is calcium silicate and wherein said superdisintegrant is selected from the group of crospovidone and croscarmellose sodium.2. A flash-melt pharmaceutical dosage form according to wherein said dispersing agent comprises from about 20 to about 70 percent by weight of said dispersing agent based on the total weight of said dosage form.3. A flash-melt pharmaceutical dosage form according to wherein said dispersing agent comprises from about 35 to about 45 percent by weight of said dispersing agent based on the total weight of said dosage form.4. A flash-melt pharmaceutical dosage form according to wherein greater than 50 percent of said dispersing agent by weight is comprised of calcium silicate.5. A flash-melt pharmaceutical dosage form according to wherein greater than 80 percent of said dispersing agent by weight is comprised of calcium silicate.6. A flash-melt pharmaceutical dosage form according to wherein said calcium silicate is orth- claim 1 , meta- or alpha triclinic-calcium silicate.7. A flash-melt pharmaceutical dosage form according to wherein said calcium silicate is comprised of a combination ...

Подробнее
Номер записи: 26
07-11-2013 дата публикации

SUBLINGUAL FENTANYL SPRAY

Номер: US20130296368A1
Автор: Goskonda Venkat R., Kattookaran Linet, Kottayil S. George, Parikh Neha, Zhu Zhongyuan
Принадлежит:

The present invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable sale thereof, or derivative thereof, suitable for administration to a patient, and methods for treatment with the formulations. 1. A sublingual formulation comprising an effective amount of fentanyl and at least one pharmaceutically acceptable excipient , the formulation providing a mean Tof about 1.28+/−0.60 hours when a dose is administered sublingually to humans.2. The sublingual formulation of claim 1 , which provides a plasma concentration after administration to humans selected from the group consisting of: about 60% of the mean Cin about 10 minutes claim 1 , about 86% of the mean Cby about 20 minutes and a combination thereof.3. The sublingual formulation of claim 1 , that when administered to humans provides a plasma concentration that is greater than about 80% of the mean Cfor about 2 hours. This application is a continuation of U.S. patent application Ser. No. 12/221,333 filed Aug. 1, 2008, which claims the benefit of U.S. Provisional Application Nos. 60/963,076, filed on Aug. 2, 2007 and 60/963,253 filed Aug. 3, 2007; the disclosures of which are hereby incorporated by reference in their entireties.The invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable salt thereof, or derivative thereof, suitable for administration to humans, and methods for treatment with the sublingual formulations.Fentanyl is a μ-opioid receptor agonist with analgesic potency approximately 80-100 times that of morphine. In clinical settings, fentanyl exerts its principal pharmacologic effects on the central nervous system. Its primary actions are analgesic and sedation.The analgesic effects of fentanyl are related to the blood level of the drug. In general, the minimum effective concentration and the concentration at which toxicity occurs rise with increasing tolerance to any and all opioids. The rate of development of ...

Подробнее
Номер записи: 27
07-11-2013 дата публикации

Fast Dissolving Tablet

Номер: US20130296385A1
Автор: Abu-Izza Khawka Abdullah, Kinter Kevin Scott, Li Vincent H., Szamosi Janos
Принадлежит:

The present invention relates to processes for the preparation of tablets which dissolve rapidly in the mouth and provide an excellent mouthfeel. The tablets of the invention comprise a compound which melts at about 37° C. or lower, have a low hardness, high stability and generally comprise few insoluble disintegrants which may cause a gritty or chalky sensation in the mouth. Convenient and economically feasible processes by which the tablets of the invention may be produced are also provided. 131-. (canceled)32. A tablet consisting of a fast dissolve granulation , an active ingredient , corn starch , one saccharide selected from the group of sorbitol , glucose , dextrose , fructose , maltose , xylitol , sucrose , lactose , glucose , galactose , mannitol , a dextrate and a maltodextrin and at least one non-saccharide containing excipient selected from the group consisting of a sowing agent , a sweetening agent , crosscarmellose sodium , a flavoring agent , a disintegrant , a glidant and a silicon dioxide ,wherein said fast dissolve granulation consists essentially of some or all of said one saccharide and one or more low melting point compound that melts or softens at or below 37° C.,wherein the said one or more low melting point compound comprises less than about 20% (wt/wt) of the fast dissolve granulation and from about 0.01% to about 2.5% (wt/wt) of the tablet, andwherein the tablet has a hardness of less than 0.5 kP.33. The tablet of wherein the one saccharide is mannitol.34. The tablet of wherein the one or more low melting point compound is one or more compounds selected from the group consisting of hydrogenated oil and partially hydrogenated oil.35. The tablet of wherein the hydrogenated oil or partially hydrogenated oil is a vegetable oil.36. A tablet consisting of a fast dissolve granulation claim 34 , an active ingredient claim 34 , corn starch claim 34 , one saccharide selected from the group of sorbitol claim 34 , glucose claim 34 , dextrose claim 34 , ...

Подробнее
Номер записи: 28
14-11-2013 дата публикации

Effervescent compositions containing n-acetylcysteine

Номер: US20130302259A1
Автор: Federico Stroppolo, Gabriele Granata, Shahbaz Ardalan
Принадлежит: ALPEX PHARMA SA

Effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine and a method of treating acetaminophen poisoning with effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine are described.

Подробнее
Номер записи: 29
28-11-2013 дата публикации

ORAL ANESTHESIA APPLICATION

Номер: US20130315842A1
Автор: Skigen Andrew L.
Принадлежит:

The present invention provides methods of administering an active agent to a localized mucous membrane in the oral cavity of a mammal, as well as oral dissolving film formed therefore. 1. A method of applying an active agent to a specific site on a mammalian mucous membrane , the method comprising the steps of:selecting an oral dissolving film comprising an active agent;identifying a specific area on a mammalian mucous membrane for treatment by the active agent;placing the oral dissolving film comprising active agent on the identified area; andtreating the identified area with the active agent comprised in the oral dissolving film, wherein the treating the identified area includes an injection or incision to the mammalian mucous membrane.2. The method of wherein the identified area comprises tissue within a mammalian oral cavity.3. The method of additionally comprising the step of administering an injection into specific area.4. The method of wherein the active agent comprises a topical anesthetic and the injection comprises administration of an additional anesthetic.5. The method of wherein the active agent comprises ethyl ester of p-aminobenzoic acid.6. The method of wherein the active agent comprises benzocaine.7. The method of wherein the active agent comprises one or more of: butamben claim 1 , dibucaine claim 1 , lidocaine claim 1 , oxybuprocaine claim 1 , pramoxine claim 1 , proparacaine claim 1 , tetracaine and proxymetacaine.8. The method of claim 1 , wherein the active agent comprises a nutraceutical.9. The method of claim 1 , wherein the active agent comprises a nutrient.10. The method of claim 1 , wherein the active agent comprises one or more of: an anti-fungal agent claim 1 , an antimicrobial agent and an antibacterial agent.11. The method of wherein the oral dissolving film additionally comprises a coloring agent and the method additionally comprises the steps of:coloring mucous membrane with the coloring agent;identifying an area treated by the ...

Подробнее
Номер записи: 30
30-01-2014 дата публикации

Foam Type Hair Dying Agent Composition

Номер: US20140026332A1
Автор: Bong-Lim Jo, Hye-Jin Moon
Принадлежит: Dong Sung Pharmaceuticals Co Ltd

Disclosed is a first composition of an oxidative permanent hair dye product that includes a C 1 -C 4 alcohol, an anionic surfactant, a nonionic surfactant, an antioxidant, an oxidative dye, a C 14 -C 22 fatty alcohol, a metal sequestering agent, an alkali agent, and purified water. According to the oxidative permanent hair dye product according to the present invention, foams generated by mixing a liquid first composition that includes a dye and a liquid second composition that includes an oxidant continuously retained on hair for more than 30 minutes, and thus hair, even close to the root, can be simply and conveniently colored in the same manner as shampooing without using a comb or brush.

Подробнее
Номер записи: 31
30-01-2014 дата публикации

EFFERVESCENT FORMULATIONS COMPRISING DEXKETOPROFEN

Номер: US20140030326A1
Автор: Bilgic Mahmut
Принадлежит:

The present invention relates to water-soluble formulations comprising the active agent dexketoprofen and to a process for production of said formulations. The present invention also relates to pharmaceutical formulations comprising dexketoprofen which is used in symptomatic treatment of mild to moderate pains such as musculoskeletal pains, dysmenorrhoea, toothache, post-operative pains. The formulations are characterized in being in effervescent form. 1. A formulation comprising dexketoprofen , pharmaceutically acceptable solvates , hydrates , salts , amorphous , and/or crystalline forms thereof , characterized in that said formulation is in water-soluble form.2. (canceled)3. The formulation according to claim 1 , characterized in that dexketoprofen is in the form of trometamol salt.4. The formulation according to claim 1 , characterized in that said formulation is in the form of water-soluble powder claim 1 , water-soluble granule claim 1 , water-soluble tablet claim 1 , effervescent powder claim 1 , effervescent granule or effervescent tablet.5. The formulation according to claim 1 , characterized in that the amount of dexketoprofen is in the range of 1 mg to 250 mg or 5 mg to 100 mg.6. (canceled)7. The formulation according to claim 1 , characterized in that said formulation comprises dexketoprofen having d90 value in the range of 250-600 μm claim 1 , 300-500 μm claim 1 , or 350-450 μm.89-. (canceled)10. The formulation according to claim 1 , characterized in that;said formulations are in water soluble tablet or effervescent tablet form; andsaid formulations comprise dexketoprofen having d90 value in the range of 250-600 μm, 300-500 μm, or 350-450 μm.1112-. (canceled)13. The formulation according to claim 1 , wherein said formulation further comprises other pharmaceutically acceptable excipients along with dexketoprofen.14. The formulation according to claim 13 , wherein said formulation comprises excipients such as binder claim 13 , carrier claim 13 , sweetener ...

Подробнее
Номер записи: 32
07-01-2016 дата публикации

ABUSE DETERRENT IMMEDIATE RELEASE FORMULATIONS COMPRISING NON-CELLULOSE POLYSACCHARIDES

Номер: US20160000703A1
Автор: FENG Kai, Gaik Jonathan, Lai Tsz Chung, Micka Alex
Принадлежит:

The present disclosure provides pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties. In particular, the pharmaceutical compositions comprise at least one pharmaceutically active ingredient, at least one non-cellulose polysaccharide, at least one hydrophilic gelling polymer, and an effervescent system. 1. A pharmaceutical composition comprising at least one active pharmaceutical ingredient (API) or a pharmaceutically acceptable salt thereof , at least one non-cellulose polysaccharide , at least one hydrophilic gelling polymer , and an effervescent system.2. The pharmaceutical composition of claim 1 , wherein at least about 70% of the API is released within about 45 minutes when dissolution is measured using an USP-approved in vitro release procedure.3. The pharmaceutical composition of claim 1 , wherein a plurality of particles having an average diameter greater than about 250 microns is formed when the composition is crushed claim 1 , ground claim 1 , or pulverized.4. The pharmaceutical composition of claim 1 , wherein the non-cellulose polysaccharide is a natural gum claim 1 , hemicellulose claim 1 , pectin claim 1 , chitin claim 1 , starch claim 1 , or a combination thereof; and the non-cellulose polysaccharide is present in an amount from about 2% to about 60% by weight of the pharmaceutical composition.5. The pharmaceutical composition of claim 1 , wherein the hydrophilic gelling polymer is a cellulose ether claim 1 , a polyalkylene oxide claim 1 , a polyacrylic acid claim 1 , or a combination thereof; and the hydrophilic gelling polymer is present in an amount from about 5% to about 80% by weight of the pharmaceutical composition.6. The pharmaceutical composition of claim 1 , wherein the effervescent system comprises a) an acid component chosen from an organic acid claim 1 , an inorganic acid claim 1 , or a combination thereof claim 1 , and b) a base component chosen from an alkali metal ...

Подробнее
Номер записи: 33
04-01-2018 дата публикации

Low-Temperature Inhalation Administration of Cannabinoid Entities

Номер: US20180000731A1
Автор: Eck Charles Raymond, Pelloni Christopher L.
Принадлежит: EP Pharma, LLC

A cannabinoid material as active agent containing formulation comprising the active agent, an HFA propellant, and optionally a co-solvent is disclosed. Also disclosed is an inhalation method of administration of the formulation without the use of heat greater than 50° C. 126-. (canceled)27. A formulation comprising:(A)(i) an extract of a cannabinoid containing plant material, said extract containing one or more first cannabinoid active agent(s) or (ii) a combination of said extract and one or more additional cannabinoid active agent(s), said additional cannabinoid active agent(s) selected from the group consisting of (a) partially or completely purified cannabinoid compounds, (b) synthetic cannabinoid compounds, and (c) mixtures thereof;(B) a hydrofluoroalkane (HFA) propellant; and(C) a co-solvent selected from the group consisting of ethanol, propanol, isopropanol, propylene, glycol, polyethylene glycol, and mixtures thereof;said HFA propellant being present in an amount of from 50% by weight to 99.99% by weight based on the entire formulation;said co-solvent, being present in an amount of from 0% by weight up to 40% by weight based on the entire formulation; andsaid extract or said combination of said extract and said additional cannabinoid active agent(s) being present, in an amount based on the total of the two most predominantly present cannabinoid active agents of from 0.01 mg/100 ul to 20 mg/100 ul of total formulation;wherein said extract contains from 1 up to 5 major cannabinoid pairs, each major cannabinoid pair consisting of the Acid and non-Acid forms thereof, wherein to be considered a major cannabinoid pair, the cannabinoid pair must be at least 20% of the total cannabinoid content of the formulation,wherein said extract is obtained in the absence of applying heat at all or in the absence of applying heat greater than 50° C.28271. The formulation of claim wherein the co-solvent is ethanol.29. The formulation of wherein the co-solvent is present in an ...

Подробнее
Номер записи: 34
02-01-2020 дата публикации

Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration

Номер: US20200000719A1
Автор: Counts David F., Cox Donald P., Dam Anup K., Stalhamer Michael E.
Принадлежит:

The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a watersoluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours. 126-. (canceled)27. A method of treating pain in a patient in need thereof comprising a step of administering to the patient a particulate composition comprising (i) naproxen, a pharmaceutically acceptable salt of said naproxen, or a combination thereof and', '(ii) a drug binding polymer comprising a silicified high density microcrystalline cellulose composed of 98% microcrystalline cellulose and 2% colloidal silicon dioxide, wherein said naproxen, said pharmaceutically acceptable salt of said naproxen, or said combination thereof is in reversible association with said drug binding polymer and in a weight ratio therewith of from about 20:1 to about 1:2; and, '(a) a biologically active core, said biologically active core comprising'}(b) a coat, said coat comprising a membrane-forming polymer, said membrane-forming polymer comprising ethylcellulose and surrounding said biologically active core, wherein the particulate ...

Подробнее
Номер записи: 35
03-01-2019 дата публикации

REDUCED FOAMING VACCINE COMPOSITIONS

Номер: US20190000978A1
Автор: Genin Noel Yves Henri Jean
Принадлежит:

The present invention relates to novel stable compressed vaccine composition comprising least one anhydrous antigenic component comprising a stabilizer susceptible to foaming when the composition is mixed with liquid diluent; and an effective amount of a sugar alcohol. 1. A process for reducing the foaming of a solid vaccine composition when mixed with a liquid diluent , wherein the composition comprises at least one anhydrous antigenic component comprising a stabilizer susceptible to foaming and an effervescent agent;wherein the process comprises adding an effective amount of die foam controlling agent which is a sugar alcohol to the solid vaccine composition, wherein the effective amount of sugar alcohol is about 15% to 40% by weight of the composition, andupon dissolution of the composition, the effervescent agent reacts and gas is formed in situ.2. The process according to claim 1 , wherein the process further comprises:compressing the solid vaccine composition to form a compressed vaccine composition.3. The process according to claim 1 , wherein the at least one anhydrous antigenic component is lyophilized or dried.4. The process according to claim 1 , wherein the stabilizer comprises one or more amino acid or salts thereof claim 1 , protein or salts thereof claim 1 , albumin claim 1 , gelatin claim 1 , or combinations thereof.5. The process according to claim 1 , wherein the at least one anhydrous antigenic component is newcastle disease virus claim 1 , infectious bronchitis virus claim 1 , fowl pox virus claim 1 , avian encephalomyelitis virus claim 1 , marek's disease virus claim 1 , trichophyton verrucosum claim 1 , avian paramyxovirus claim 1 , mycobacterium paratuberculosis claim 1 , meleagrid herpesvirus claim 1 , orf virus claim 1 , or sheep pox virus.6. The process according to claim 1 , wherein the at least one anhydrous antigenic component is newcastle disease virus or infectious bronchitis virus.7. The process according to claim 1 , wherein the ...

Подробнее
Номер записи: 36
11-01-2018 дата публикации

IMMEDIATE RELEASE, ABUSE DETERRENT PHARMACEUTICAL COMPOSITIONS

Номер: US20180008532A1
Автор: Battu Sunil K., Burge Eric A., Diezi Thomas A., Herman Clifford J., Park Jae Han, Raman Siva N.
Принадлежит:

The present disclosure provides pharmaceutical compositions and processes for making solid dosage form pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties. The pharmaceutical compositions provided herein comprise at least one pharmaceutically active ingredient, at least one low molecular weight hydrophilic polymer, at least one high molecular weight hydrophilic polymer, and an effervescent system. 1. A solid dosage form comprising at least one active pharmaceutical ingredient (API) or a pharmaceutically acceptable salt thereof , at least one low molecular weight hydrophilic polymer , at least one high molecular weight hydrophilic polymer , and an effervescent system , wherein the at least one low molecular weight hydrophilic polymer has an average molecular weight of no more than 200 ,000 Daltons , the at least one high molecular weight hydrophilic polymer has an average molecular weight of at least 400 ,000 Daltons , and the solid dosage form has been heated at a temperature from about 50° C. to about 80° C. to plasticize and/or cure at least one of the low or high molecular weight hydrophilic polymers.2. The solid dosage form of claim 1 , wherein the at least one low molecular weight hydrophilic polymer is chosen from a polyalkylene oxide claim 1 , a cellulose ether claim 1 , a polyalkylene glycol claim 1 , a poloxamer claim 1 , or combination thereof; and the at least one low molecular weight hydrophilic polymer is present in an amount from about 5% to about 50% by weight of the solid dosage form.3. The solid dosage form of claim 1 , wherein the at least one high molecular weight hydrophilic polymer is chosen from a polyalkylene oxide claim 1 , a cellulose ether claim 1 , a polysaccharide claim 1 , or combination thereof; and the at least one high molecular weight hydrophilic polymer is present in an amount from about 0.1% to about 30% by weight of the solid dosage form.4. The solid dosage form of ...

Подробнее
Номер записи: 37
14-01-2021 дата публикации

REGENERATIVE CO2 TREATMENT APPARATUS AND METHOD

Номер: US20210008102A1
Автор: Tornatore Renee
Принадлежит:

The present technology provides regenerative treatment methods and apparatus to promote regeneration of target biological tissue. Regenerative treatments include the subcutaneous and cutaneous application of carbon dioxide. Regenerative treatment methods include an initial treatment phase and a maintenance treatment phase. Regenerative treatment apparatus include effervescent mineral compositions for cutaneous application of carbon dioxide. 1. A regenerative treatment method for treating target biological tissue within a target area of a patient , the method comprising:an initial treatment phase comprising at least one initial phase therapy session and at least one initial phase personal administration, wherein each initial phase therapy session includes at least subcutaneous application of carbon dioxide in the target area and each initial phase personal administration includes at least cutaneous application of carbon dioxide to the target area; anda maintenance treatment phase after the initial treatment phase, the maintenance phase comprising at least one maintenance phase therapy session and at least one maintenance phase personal administration, wherein each maintenance phase therapy session includes at least subcutaneous application of carbon dioxide in the target area and each maintenance phase personal administration includes at least cutaneous application of carbon dioxide to the target area.2. The regenerative treatment method of claim 1 , wherein each initial phase therapy session further comprises cutaneous administration of carbon dioxide to the target area.3. The regenerative treatment method of claim 1 , wherein each therapy session further comprises physical manipulation of the target area.4. The regenerative treatment method of claim 1 , wherein each therapy session further includes a secondary treatment of the target area5. The regenerative treatment method of claim 4 , wherein the secondary treatment comprises electrical stimulation.6. The ...

Подробнее
Номер записи: 38
10-01-2019 дата публикации

METHOD TO FORMULATE AND PRODUCE DIETARY SUPPLEMENTS OR FUNCTIONAL FOODS IN EFFERVESCENT SPHEROIDAL SHAPED TABLETS

Номер: US20190008761A1
Автор: ALEVIZACHE DRAGOS
Принадлежит:

This application discloses effervescent spheroidal shaped tablets for dietary supplements, nutraceuticals, or functional foods, and methods for making and producing the tablets. 1. A method of making an effervescent spheroidal tablet by the steps of:a. Sifting one or more acids, one or more carbonates, and one or more dietary ingredients with a stainless steel sieve to create a mixture of components;b. Mixing the mixture in a blender, and concurrently spraying mixing spray onto the mixture, until the mixture and mixing spray are homogenized;c. Discharging the mixture onto a drying tray;d. Drying the mixture in a preheated oven for a period of approximately 90 minutes, concurrently agitating the mixture;e. Optionally allowing the mixture to cool to room temperature; andf. Loading the mixture into a tablet press and operate tablet press to create a tablet.2. The method of claim 1 , wherein step a) further includes sifting one or more super-disintegrant agents claim 1 , one or more binders claim 1 , one or more lubricants claim 1 , and one or more sweeteners to include in the mixture of components.3. The method of claim 1 , wherein the one or more dietary ingredient is selected from a group consisting of caffeine anhydrous claim 1 , tea extracts claim 1 , purine alkaloids claim 1 , theacrine claim 1 , methyl liberine claim 1 , 1 claim 1 ,3 claim 1 ,7 trimethyluric acid claim 1 , 1 claim 1 ,3 claim 1 ,7 trimethyluric acid sodium salts claim 1 , yohimbine claim 1 , alpha yohimbine claim 1 , yohimbine hydrochloride claim 1 , huperzin A claim 1 , vinitrox claim 1 , creatine claim 1 , creatine salts claim 1 , buffered creatine claim 1 , beta alanine claim 1 , gamma butyrobetaine ethyl ester claim 1 , gamma butyrobetaine ethyl ester hydrochloride claim 1 , gammabutyrobetaine ethyl ester claim 1 , medium chain triglycerides claim 1 , carnitine claim 1 , L-carnitine claim 1 , fumarate claim 1 , tartrate claim 1 , paradoxine claim 1 , dihydrocapsiate claim 1 , branch chain ...

Подробнее
Номер записи: 39
10-01-2019 дата публикации

BLACK CHINESE WOLFBERRY EFFERVESCENT TABLET AND PREPARATION METHOD THEREOF

Номер: US20190008914A1
Автор: Gao Lin
Принадлежит:

The invention discloses a black Chinese wolfberry effervescent tablet and a preparation method thereof. The preparation method comprises the following steps: 1. lyophilized powder of black Chinese wolfberry extract and part of citric acid are crushed and mixed; 2. the crushed and mixed material is taken out, added with a water-soluble starch and mixed again, and the resulting mixture is prepared into a soft material by taking ethanol as a wetting agent, then prepared into granules and dried until the water content is controlled at 2.2-3.5%; and 3. the granules prepared in step 2 are mixed with an alkali source, the remaining citric acid, sucrose and an encapsulant and then pressed into effervescent tablets. 1. A preparation method of a black Chinese wolfberry effervescent tablet prepared from lyophilized powder of black Chinese wolfberry extract , citric acid , an alkali source , a water-soluble starch , sucrose and an encapsulant as raw materials comprises the following steps:(1) lyophilized powder of black Chinese wolfberry extract and part of citric acid are crushed and mixed;(2) the crushed and mixed material is taken out, added with a water-soluble starch and mixed again, and the resulting mixture is prepared into a soft material by taking ethanol as a wetting agent, then prepared into granules and dried until the water content is controlled at 2.2-3.5%; and(3) the granules prepared in step (2) are mixed with an alkali source, the remaining citric acid, sucrose and an encapsulant and then pressed into effervescent tablets.2. The preparation method of a black Chinese wolfberry effervescent tablet according to claim 1 , wherein the raw materials consist of 25-45% of citric acid claim 1 , 5-10% of an alkali source claim 1 , 3-7% of a water-soluble starch claim 1 , 1-3% of an encapsulant claim 1 , 0.5-5% of sucrose and 40-60% of lyophilized powder of black Chinese wolfberry extract based on the weight percentage.3. The preparation method of a black Chinese ...

Подробнее
Номер записи: 40
19-01-2017 дата публикации

EFFERVESCENT COMPOSITION IN SOLID FORM FOR USE IN VAGINAL APPLICATIONS FOR THE TREATMENT OF VAGINAL INFECTIONS

Номер: US20170014335A1
Автор: Mogna Giovanni, Mogna Luca, Strozzi Gian Paolo
Принадлежит:

The present invention relates to an effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections. 114-. (canceled)15. A medicament comprising an effervescent composition in solid form comprising:an acid-base system comprising an organic acid and a salt of the carbonate and/or bicarbonate anion; said salt being present in an amount comprised from 1 to 15% by weight, relative to the total weight of the composition,a mixture comprising microcrystalline cellulose and arabinogalactan,{'i': Candida albicans, Candida glabrata, Candida parapsilosis, Candida krusei, Candida tropicalis, Gardnerella vaginalis, Trichomonas vaginalis, Neisseria gonorrhoeae, Escherichia coli', 'Haemophilus ducreyi,, 'at least one probiotic bacterial strain having the ability to reduce and/or eliminate the presence of pathogenic agents selected from the group comprising: , Herpes simplex and'}the effervescent composition being formulated for treatment of a vaginal infection.16. The medicament in accordance with claim 15 , wherein said composition is in the form of a tablet claim 15 , ovule claim 15 , lozenge or granules.17. The medicament in accordance with claim 15 , wherein the salt of carbonate and/or bicarbonate anion is present in an amount comprised from 3 to 13% by weight claim 15 , relative to the total weight of the composition.18. The medicament in accordance with claim 15 , wherein the acid-base system consists of sodium bicarbonate and citric acid claim 15 , and wherein the sodium bicarbonate is present in an amount comprised from 3 to 13% by weight claim 15 , relative to the total weight of the composition.19Lactobacillus plantarum, Lactobacillus pentosus, Lactobacillus casei, Lactobacillus caseiparacasei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus delbrueckii, Lactobacillus delbrueckiibulgaricus, Lactobacillus delbrueckiidelbrueckii, Lactobacillus fermentum, Lactobacillus gasseri, Lactobacillus reuteri, ...

Подробнее
Номер записи: 41
18-01-2018 дата публикации

USE OF MTOR INHIBITORS TO PREVENT AND REGRESS EDHESIONS AND FIBROSIS

Номер: US20180015074A1
Автор: KELLOGG Dean L.
Принадлежит:

Embodiments of the disclosure include preventing or reducing adhesion between two tissues and/or organs in an individual subjected to a procedure and/or preventing or reducing one or more keloids in an individual subjected to a procedure by providing to the individual an effective amount of a composition comprising one or more inhibitors of an mTOR pathway no earlier than about 4 days following the procedure. 1. A method ofa) preventing or reducing adhesion between two tissues and/or organs in an individual subjected to a procedure, and/orb) preventing or reducing one or more keloids in an individual subjected to a procedure;comprising the step of providing to the individual an effective amount of a composition comprising one or more inhibitors of an mTOR pathway no earlier than about 4 days following the procedure.2. The method of claim 1 , wherein the inhibitor of an mTOR pathway is rapamycin and/or a rapamycin analog.3. The method of claim 2 , wherein the rapamycin analog is selected from the group consisting of temsirolimus claim 2 , everolimus claim 2 , deforolimus claim 2 , CCI-779 claim 2 , curcumin claim 2 , Green tea extract standardised to 70% EGCG claim 2 , transresveratrol claim 2 , fisetin claim 2 , salicin extracted from white willow claim 2 , and a combination thereof.4. The method of claim 1 , wherein the inhibitor of the mTOR pathway is an ATP-competitive mTOR kinase inhibitor.5. The method of claim 4 , wherein the ATP-competitive mTOR kinase inhibitor is selected from the group consisting of AZD8055 claim 4 , Torin1 claim 4 , PP242 claim 4 , PP30 and a combination thereof.6. The method of any of - claim 4 , wherein the adhesions are between abdominal claim 4 , pelvic claim 4 , or thoracic organs and/or with the walls of the abdominal claim 4 , pelvic claim 4 , or thoracic cavities.7. The method of claim 6 , wherein the pelvic adhesions involve a reproductive organ claim 6 , the urinary bladder claim 6 , the pelvic colon claim 6 , and/or the rectum. ...

Подробнее
Номер записи: 42
21-01-2016 дата публикации

PHARMACEUTICAL COMPOSITION FOR PREPARING DRUG DELIVERY NANO/MICRO BUBBLES

Номер: US20160015629A1
Автор: CHUANG Er-Yuan, Lin Po-Yen, Sung Hsing-Wen
Принадлежит:

The pharmaceutical composition includes a drug layer comprising an active ingredient, a surfactant, an acidic component and an effervescent ingredient. The active ingredient comprises a nucleic acid, a peptide or a protein. The acidic component and effervescent ingredient of the drug layer are dissolved in the water to react for generating carbon dioxide and bubbles thereof. The surfactants surround the carbon dioxide gas core and form a double-layer structure having an inner layer and outer layer. The active ingredient is embedded in a gap formed between the inner layer and the outer layer of the double-layer structure.

Подробнее
Номер записи: 43
23-01-2020 дата публикации

Combinations of diclofenac, h2 receptor antagonists and alkali metal bicarbonates for the treatment of pain and inflammation

Номер: US20200022936A1
Автор: Mehmet Nevzat PISAK
Принадлежит: Individual

A combination comprising: a) diclofenac or a pharmaceutically acceptable salt thereof, b) an H2 receptor antagonist, preferably famotidine or a pharmaceutically acceptable salt thereof, and c) an alkali metal carbonate or bicarbonate, preferably potassium bicarbonate for use in the treatment of pain and inflammation.

Подробнее
Номер записи: 44
02-02-2017 дата публикации

Methods and Compositions for Delivering an Extract of Piper Methysticum

Номер: US20170028009A1
Автор: Kambouris Ambrosios
Принадлежит: Kambouris Shares PTY Ltd.

The present invention provides a method for delivering a extract to an animal in need thereof, the method comprising the steps of: (i) administering the extract orally to the animal, and (ii) administering an effervescent agent orally to the animal to cause the generation of an effervescence product within the alimentary tract of the animal, wherein the extract and effervescence product co-locate at a site in the alimentary tract of the animal such that a psychoactive effect of the extract is improved relative to a method whereby there is no co-location of an effervescence product and the extract. The method may be useful in altering the neurological state of a subject, to decrease anxiety, increase relaxation, decrease wakefulness, increase happiness, increase cheerfulness, or improve cognitive ability. 2. The method of wherein the effervescent agent consists of claim 1 , or comprises claim 1 , a chemical compound capable of releasing a gas upon exposure to moisture.3. The method of wherein the effervescent agent consists of claim 1 , or comprises claim 1 , an alkali metal carbonate salt claim 1 , optionally in combination with an organic acid.4. The method of wherein the effervescence product is a gas5. The method of wherein the gas is carbon dioxide.6P methysticum. The method of wherein the extract is a dried preparation.7. The method of wherein the act of administering the extract occurs substantially contemporaneously with the act of administering the effervescent agent.8. (canceled)10P methysticum. The method of wherein (i) the onset of alteration to neurological state is more rapid and/or (ii) the altered neurological state is of longer duration and/or (ii) the neurological effect is subjectively or objectively greater relative to a method whereby there is no co-location of an effervescence product and the extract.11. The method of wherein the alteration of neurological state is a decrease in anxiety and/or an increase in relaxation and/or a decrease in ...

Подробнее
Номер записи: 45
17-02-2022 дата публикации

A SUSTAINED RELEASE COMPOSITION COMPRISING A METHYLCELLULOSE

Номер: US20220047498A1
Автор: Petermann Oliver
Принадлежит:

A sustained release composition for oral administration comprises a physiologically active ingredient mixed with a methylcellulose, wherein 1. A sustained release composition for oral administration comprising a physiologically active ingredient mixed with a methylcellulose , whereinthe methylcellulose has anhydroglucose units joined by 1-4 linkages and wherein hydroxy groups of anhydroglucose units are substituted with methyl groups such that the s23/s26 is more than 0.27,wherein s23 is the molar fraction of anhydroglucose units wherein only the two hydroxy groups in the 2- and 3-positions of the anhydroglucose unit are substituted with methyl groups andwherein s26 is the molar fraction of anhydroglucose units wherein only the two hydroxy groups in the 2- and 6-positions of the anhydroglucose unit are substituted with methyl groups, andwherein the concentration of methylcellulose is from 0.1% to 10% by dry weight of the active ingredient.2. The composition of claim 1 , wherein the concentration of methylcellulose is 0.2-5% claim 1 , preferably 0.5-4% claim 1 , more preferably 0.75-2% and still more preferably 0.8-1.5% claim 1 , by dry weight of the active ingredient.3. The composition of claim 1 , wherein the concentration of methylcellulose is about 1% by dry weight of the active ingredient.4. The composition of comprising a methylcellulose wherein hydroxy groups of anhydroglucose units are substituted with methyl groups such that s23/s26 is between 0.27 and 0.36 claim 1 , preferably between 0.27 and 0.33 claim 1 , more preferably between 0.27 and 0.30.5. The composition of wherein the methylcellulose has a DS(methyl) of from 1.55 to 2.25.6. The composition of claim 1 , wherein the methylcellulose has a viscosity of from 2.4 to 10000 mPa·s claim 1 , measured as 2 wt. % aqueous solution at 5° C. at a shear rate of 10 s.7. The composition of claim 1 , wherein the methylcellulose comprises at least 50% claim 1 , preferably 60-100% claim 1 , by weight of a polymeric ...

Подробнее
Номер записи: 46
17-02-2022 дата публикации

ORAL DISSOLVABLE FILM WITH PORES EXTENDING THERETHROUGH

Номер: US20220047504A1
Автор: Bernardo Jose, Davidson Robert, Espinoza Maribel, Gigi Vered, Patel Bhaumik, Ruhl Steven
Принадлежит: Cure Pharmaceutical Holding Corp.

An oral dissolvable film, methods of making the oral dissolvable film, and methods of using the oral dissolvable film. The oral dissolvable film contains pores located therein. 1. An oral dissolvable film comprising a film matrix , the film matrix comprising a film forming agent , one or more active pharmaceutical ingredients (APIs) , and one or more pharmaceutically acceptable excipients; the oral dissolvable film contains pores extending therethrough;', 'upon placing in the oral cavity, the oral dissolvable film disintegrates within 90 seconds;', 'the oral dissolvable film has a thickness of 0.05 mm to 1.00 mm;', 'the oral dissolvable film is in a unit dosage form;', 'the oral dissolvable film has a mass of 180-260 mg;', 'the oral dissolvable film has a drug; load of API of 0.5 wt. % to 40 wt. %;', {'sup': 3', '3, 'the oral dissolvable film has a density of 0.40 g/cmto 0.90 g/cm.'}], 'wherein,'}2. The oral dissolvable film of claim 1 , wherein the oral dissolvable film contains pores extending partially therethrough the oral dissolvable film.3. The oral dissolvable film of claim 1 , wherein the oral dissolvable film contains pores extending completely therethrough the oral dissolvable film.4. The oral dissolvable film of claim 1 , wherein the pores are in the form of a hole claim 1 , aperture claim 1 , channel claim 1 , crack claim 1 , cavity claim 1 , perforation claim 1 , cleft claim 1 , cranny claim 1 , fissure claim 1 , gap claim 1 , crevice claim 1 , incision claim 1 , recess claim 1 , socket claim 1 , opening claim 1 , groove claim 1 , pocket claim 1 , or slit.5. The oral dissolvable film of claim 1 , comprising a single active pharmaceutical ingredient (API).6. The oral dissolvable film of claim 1 , wherein the film forming agent of the film matrix is ingestible.7. The oral dissolvable film of claim 1 , wherein the film forming agent of the film matrix is water-soluble claim 1 , water swellable claim 1 , or a combination thereof.8. The oral dissolvable film ...

Подробнее
Номер записи: 47
04-02-2021 дата публикации

MULTI-LAYER ORAL THIN FILM

Номер: US20210030668A1
Автор: LINN Michael, Schmitz Christoph
Принадлежит:

Described are: a multi-layer oral thin film, comprising at least two layers arranged one on top of the other, which each comprise at least one water-soluble polymer, these at least two layers being connected to one another by at least one sealing, characterised in that the at least one sealing is not provided over the entire surface; a method for producing same; and use thereof as a medicament. 1. A multi-layer oral thin filmy comprising at least two layers arranged one on top of the other , wherein each layer comprises at least one water-soluble polymer , the at least two layers being connected to one another by at least one sealing , wherein the at least one sealing is not provided over an entire surface.2. The multi-layer oral thin film according to claim 1 , wherein the at least one sealing is applied in such a way that at least one overlapping edge of the at least two layers arranged one on top of the other is not closed by a sealing.3. The multi-layer oral thin film according to claim 1 , wherein the at least one water-soluble polymer comprises a heat-sealable polymer.4. The multi-layer oral thin film according to claim 3 , wherein the at least one sealing not provided over the entire surface comprises a heat sealing not provided over the entire surface.5. The multi-layer oral thin film according to claim 1 , wherein the at least one water-soluble polymer comprises polyvinyl alcohol claim 1 , pullulan claim 1 , polyethylene oxide claim 1 , polyethylene glycol and/or copolymers thereof.6. The multi-layer oral thin film according to claim 1 , wherein at least one layer of the multi-layer oral thin film comprises at least one pharmaceutical active ingredient.7. The multi-layer oral thin film according to claim 1 , wherein the at least two layers are connected to one another by precisely one sealing not provided over the entire surface.8. The multi-layer oral thin film according to claim 1 , wherein the at least two layers are connected to one another by two ...

Подробнее
Номер записи: 48
11-02-2016 дата публикации

EFFERVESCENT MULTI-VITAMIN/MINERAL ADDITIVE FOR COFFEE AND TEA

Номер: US20160038405A1
Автор: Murphy Kevin
Принадлежит:

A water soluble micronutrient composition that infuses vitamins and minerals into coffee and tea designed to maximize bio-absorption in consideration of pH levels, temperature and caffeine. The composition contains water-soluble and oil-soluble vitamins and minerals in bioavailable forms contained in a composition consisting of -% of a vitamin blend with -% of one or more minerals selected from the group consisting of calcium, magnesium, iron, zinc, copper and manganese, -% citric acid, -% of one or more alkali or alkaline earth metal bicarbonates or carbonates, -% flavoring agent, -% of a sweetening agent. When dissolved in liquid a specific amount of micronutrients are infused into the drink by way of a soluble, bioavailable form in the amount of approximately -% of the US RDA of multiple vitamins and trace minerals along with a desired flavor to enhance the coffee, tea or other liquid. 1. A water soluble micronutrient (vitamin and/or mineral) composition for direct use as an additive in coffee and tea , comprising:at least one of a vitamin additive, a literal additive and a flavor additive;at least one pH stabilizing agent that stabilizes a pH of the liquid into which the tablet is to be placed;at least one effervescence agent having sufficient effervescence to separate the tablet or powder upon placement in the coffee and tea; andat least one solubility agent that facilitates expeditious dissolution of the composition in the coffee and tea into which it is placed; wherein a percentage of components in the tablet are in a range of:Vitamin additive 1-5%;Mineral additive 5-15%;Flavor additive 10-20%;Base Reactor(s) 15-30% Acid Reactor(s) 10-30%;Binding Agent 10-30%;Lubricant(s) 5-10%.2. The effervescent vitamin and mineral composition of wherein the composition comprises a tablet and a dosage unit of said tablet is about two to six grams.3. The effervescent vitamin and mineral composition of wherein a dosage unit of said composition contains between about 25 and ...

Подробнее
Номер записи: 49
06-02-2020 дата публикации

ORAL MEDICATION FORMULATIONS

Номер: US20200038318A1
Автор: HUGHES Jamie, POPP Cris, WARDROP-BROWN Bradley
Принадлежит:

A preparation comprising an active ingredient, a suspension base and an effervescent agent wherein the active ingredient comprises one or more B vitamins. The suspension base comprises at least one of inulin, dextrins such as maltodextrin, cellulose derivatives, gums such as xanthan gum, and other hydrocolloids; preferably a combination of inulin and xanthan gum. 122.-. (canceled)23. An effervescent formulation for ameliorating or reducing the signs of a brain-related condition , comprising at least one active agent , at least one pharmaceutically acceptable effervescent acid , at least one effervescent base and at least another excipient wherein the active agent comprises L-methylfolate.24. The composition for ameliorating or reducing the signs of a brain-related condition according to claim 23 , comprising: L-methylfolate or a physiologically acceptable salt claim 23 , or ester thereof; flavour additive; inulin; sucralose; a sweetener; sodium carbonate; citric acid anhydrous; xanthan gum; sodium bicarbonate.25. The composition according to claim 24 , comprising Cyanocobalamin or a physiologically acceptable salt or ester thereof.26. The composition according to claim 24 , comprising:0.1-100 mg L-methylfolate or a physiologically acceptable salt, or ester thereof;80 to 8000 mg inulin;3 to 300 mg sucralose;glucose;40 to 5000 mg sodium carbonate;150 to 15,000 mg citric acid anhydrous;1 to 200 mg xanthan gum 200 mesh;40 to 5000 mg sodium bicarbonate.27. The composition according to claim 24 , comprising: 10 to 20 mg L-methylfolate or a physiologically acceptable salt claim 24 , ester or derivative thereof.28. The composition according to claim 24 , comprising: 750 to 900 mg inulin.29. The composition according to claim 24 , comprising: 25 to 35 mg sucralose.30. The composition according to claim 24 , comprising: 750 to 900 mg glucose.31. The composition according to claim 24 , comprising: 400 to 600 mg sodium carbonate.32. The composition according to claim 24 , ...

Подробнее
Номер записи: 50
06-02-2020 дата публикации

MINERAL, NUTRITIONAL, COSMETIC, PHARMACEUTICAL, AND AGRICULTURAL COMPOSITIONS AND METHODS FOR PRODUCING THE SAME

Номер: US20200038435A1
Автор: Blotsky Roger D., Figueroa Ramon
Принадлежит: Core Intellectual Properties Holdings, LLC

Mineral, cosmetic, pharmaceutical, agricultural, nutraceutical, and other compositions are produced using a mineral composition containing minimal concentrations of cadmium, lead, arsenic, and mercury and containing relatively high concentrations of micro and macro mineral elements, of rare earth elements, of calcium, and of silica. The mineral concentrations are produced by processing naturally occurring clay soil to concentrate mineral elements naturally occurring in the soil. 1. A mineral supplement prepared by a process comprising the steps of:admixing a clay soil, a mixture of clay soils, or a mixture of clay soils and leonardite, with water in an amount at least two times the weight of the soil and an acid to produce a water-acid-soil slurry, wherein the amount of acid is 0.25% to 7.5% of the weight of the water;allowing solids from the water-acid-soil slurry to settle;separating the liquid of the water-acid-soil slurry from the settled solids wherein the solids comprise substantially all of the silica and aluminum from the clay soil, mixture of clay soils, or mixture of clay soils and leonardite; andconcentrating the separated liquid to form a liquid extracted mineral element composition comprising a lower amount of silica and aluminum than the clay soil, a mixture of clay soils, or a mixture of clay soils and leonardite.2. The mineral supplement according to claim 1 , wherein the pH of the extracted mineral element composition is less than 4.5.3. The mineral supplement according to claim 1 , further comprising a step of purifying the liquid extracted mineral element composition by reverse osmosis.4. The mineral supplement according to claim 1 , wherein the acid is citric acid.5. The mineral supplement according to claim 1 , wherein the acid is phosphoric acid.6. The mineral supplement according to claim 1 , further comprising a step of drying the liquid extracted mineral element composition to form a dry extracted mineral element composition.7. The mineral ...

Подробнее
Номер записи: 51
18-02-2016 дата публикации

Children's Medication Delivery Device

Номер: US20160045433A1
Автор: Whitney Debbie
Принадлежит:

A children's medication delivery device for delivering liquid medication to a young child in a form that is palatable and attractive to facilitate administering medication to the child. The device includes a shell comprising a gummy candy composition. The shell defines an interior space within the shell. A medication is positioned in the interior space of the shell wherein the medication is enclosed by and contained in the shell. 1. A children's medication delivery device comprising:a shell, said shell comprising a gummy candy composition, said shell defining an interior space within said shell; anda medication positioned in said interior space of said shell wherein said medication is enclosed by and contained in said shell.2. The device of claim 1 , further comprising said medication being a liquid.3. The device of claim 2 , further comprising said medication being flavored.4. The device of claim 1 , further comprising said interior space being defined by an interior wall within said shell claim 1 , said interior wall defining said interior space as being prolate spheroid.5. The device of claim 1 , further comprising said shell having an outer surface shaped to define an animal-like shape.6. The device of claim 5 , further comprising said animal-like shape resembling a bear.7. The device of claim 1 , further comprising said gummy candy composition of said shell being gelatinous.8. A children's medication delivery device comprising:a shell, said shell comprising a gummy candy composition, said shell defining an interior space within said shell, said gummy candy composition of said shell being gelatinous, said interior space being defined by an interior wall within said shell, said interior wall defining said interior space as being prolate spheroid, said shell having an outer surface shaped to define an animal-like shape, said animal-like shape resembling a bear; anda medication positioned in said interior space of said shell wherein said medication is enclosed by ...

Подробнее
Номер записи: 52
16-02-2017 дата публикации

TREATMENT OF THROMBOCYTOPENIA USING ORALLY ADMINISTERED INTERFERON

Номер: US20170042974A1
Автор: CUMMINS Martin Joseph, LEE Ching-Yuan, YEH Chau-Ting
Принадлежит:

An interferon composition is provided for enhancing the platelet count, reducing the recurrence rate of hepatitis, and/or improving the social function of hepatitis patients. The method comprises administering a low dose of IFN (about 5 IU to about 2500 IU of IFN-alpha) to a patient in need thereof. In one embodiment the IFN is alpha IFN or beta IFN, and more particularly, in one embodiment the administered biologically active IFN is human alpha IFN. 117.-. (canceled)18. A method of enhancing the platelet count of a patient having thrombocytopenia , the method comprising:identifying a patient with platelet blood levels of less than 150,000 platelets per microliter,wherein the normal level of blood platelets in the patient is at or above 150,000 platelets per microliter, andorally administering a daily dosage of about 500 IU of interferon-alpha to the patient to stimulate a more rapid increase of blood platelets to a normal level of blood platelets in the patient.19. The method of claim 18 , wherein the patient is infected with hepatitis C virus.20. The method of claim 18 , wherein the thrombocytopenia is due to a reduction of blood platelets in the patient receiving intravenous interferon.21. The method of claim 18 , wherein the interferon-alpha is orally administered bucally.22. The method of claim 18 , wherein the interferon-alpha comprises a first interferon-alpha and a second interferon-alpha.23. The method of claim 22 , wherein the first interferon-alpha is an interferon-α2b and the second interferon-alpha is an interferon-α8a.24. The method of claim 22 , wherein the ratio of the first interferon-alpha to the second interferon-alpha is 3:1.25. The method of claim 18 , wherein the interferon-alpha is formulated in a liquid or a saliva-soluble lozenge dosage form.26. The method of claim 25 , wherein the interferon-alpha is formulated as the saliva-soluble lozenge dosage form claim 25 , and orally administering the interferon-alpha comprises:introducing the saliva ...

Подробнее
Номер записи: 53
03-03-2022 дата публикации

EFFERVESCENT TABLETS

Номер: US20220062163A1
Автор: Diorio Christopher, Schaible David
Принадлежит: PHARMACANNIS LABS LLC

Effervescent self-emulsifying drug delivery system formulations for oral administration of water-insoluble cannabinoids are disclosed.

Подробнее
Номер записи: 54
14-02-2019 дата публикации

Solid Compositions Comprising a Glucokinase Activator and Methods of Making and Using the Same

Номер: US20190046645A1
Автор: BENJAMIN Eric, Rapuru Siva Kumar, THORSTEINSSON Thorsteinn
Принадлежит:

The invention relates to solid compositions comprising {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid, and methods of making and using such solid compositions. 1. A solid composition comprising wet granulated particles which comprise {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid , a binder , and a water-soluble surfactant ,wherein the binder comprises polyvinylpyrrolidone.2. The solid composition of claim 1 , wherein at least 80% by weight of the wet granulated particles have a particle size that is between 1 μm and 1 mm.3. The solid composition of claim 1 , wherein at least 80% by weight of the wet granulated particles have a particle size that is between 1 μm and 500 μm.4. The solid composition of claim 1 , wherein at least 90% of the particles of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid used in the wet granulation process have a particle size between 0.1 μm and 10 μm.5. The solid composition of claim 4 , wherein at least 85% of the particles of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid used in the wet granulation process have a particle size between 0.4 μm and 6 μm.6. The solid composition of claim 1 , wherein the water-soluble surfactant is a sulfuric acid alkyl ester salt claim 1 , a bile acid salt claim 1 , a propylene glycol fatty acid mono- or diester claim 1 , a polyethylene glycol fatty acid ester claim 1 , a polyoxyethylene sorbitan fatty acid ester claim 1 , a polyoxyethylene-polyoxypropylene copolymer or block copolymer surfactant claim 1 , a polyoxyethylene derivative of a tocopherol or a tocotrienol claim 1 , a polyoxyethylene derivative of a natural oil or wax claim 1 , a sorbitan fatty acid ester claim 1 , or a mixture thereof.7. The solid composition of claim 1 , wherein the water-soluble surfactant is a sulfuric acid alkyl ester salt claim 1 , a polyoxyethylene ...

Подробнее
Номер записи: 55
03-03-2016 дата публикации

IMMEDIATE-RELEASE BOLUS

Номер: US20160058700A1
Автор: BONTE Julien, LAZA-KNOERR Anca L.
Принадлежит:

The subject of the invention is a veterinary product or a nutrition product intended in particular for the prevention and treatment of hypocalcaemia in ruminant animals. The product is in the form of a bolus comprising calcium chloride and an effervescent mixture. Advantageously, the bolus enables a high bioavailability of the calcium and does not cause lesions on the digestive tract of the animal. 1. Anhydrous bolus in the form of a solid tablet , comprising:calcium in a content of 10% to 50% by weight of the weight of the bolus, andcalcium chloride, an acidic compound and a basic compound, that are in the form of powders,wherein the acidic compound and the basic compound are in a sufficient amount for reacting together and for generating a release of gas in an aqueous medium.2. Bolus according to claim 1 , wherein calcium chloride is calcium chloride dihydrate.3. Bolus according to claim 1 , wherein calcium chloride is a powder having a Dof less than 1.5 mm and a Dof less than 0.5 mm.4. Bolus according to claim 1 , wherein the basic compound represents from 2% to 35% of the weight of the bolus.5. Bolus according to claim 1 , wherein the acidic compound represents from 7% to 15% by weight of the weight of the bolus.6. Bolus according to claim 1 , wherein the basic compound is a carbonate salt or a bicarbonate salt.7. Bolus according to claim 1 , wherein it comprises at least one trace element or one vitamin claim 1 , for example magnesium claim 1 , B-group vitamins claim 1 , such as niacin (B3) claim 1 , folic acid (B9) claim 1 , riboflavin (B2) claim 1 , pantothenic acid (B5) and cobalamin (B12) claim 1 , or vitamin D3 (cholecalciferol).8. Method for the treatment or prevention of hypocalcaemia in a ruminant animal in need thereof claim 1 , comprising a step of administering a bolus according to .9. Process for producing a bolus according to claim 1 , said process comprising the steps of:mixing of the calcium chloride, the basic compound and the anhydrous acidic ...

Подробнее
Номер записи: 56
20-02-2020 дата публикации

PHARMACEUTICAL PAIN RELIEF COMPOSITION

Номер: US20200054588A1
Автор: CHIBANE Mohamed, SERRANO Jean Jacques
Принадлежит: PROMINDUS SARL

The present invention thus relates to an anhydrous pharmaceutical composition comprising an anti-inflammatory principle chosen from the derivatives of aryl-propionic acid, an antispasmodic in the triphenol family and an effervescent excipient. 1. Anhydrous pharmaceutical composition comprising an anti-inflammatory principle chosen from the derivatives of aryl-propionic acid , an antispasmodic of a triphenol and a buffered effervescent excipient.2. Composition according to claim 1 , wherein the anti-inflammatory chosen from derivatives of aryl-propionic acid is chosen from the group consisting of ketoprofen claim 1 , dexketoprofen claim 1 , naproxen claim 1 , ibuprofen and flurbiprofen.3. Composition according to claim 1 , wherein that the antispasmodic of a triphenol family is 1 claim 1 ,3 claim 1 ,5-benzenetriol.4. Composition according to claim 1 , wherein the buffered effervescent excipient comprises an association of at least one organic acid and/or at least one organic acid salt with at least one strong base and/or at least one salt of a strong base.5. Composition according to claim 1 , wherein the effervescent excipient comprises an association of citric acid+sodium bicarbonate.6. Composition according to claim 1 , which is in a form of effervescent tablets claim 1 , effervescent granules or effervescent powders.7. A method of orally treating spasmodic disorders chosen from spasmodic colitis claim 1 , hepatic colic claim 1 , renal colic and dysmenorrhea which comprises orally administering to a patient in need thereof the composition according to .8. The method according to claim 7 , wherein said dysmenorrhea is secondary dysmenorrheas associated with an endometriosis.9. The method according to claim 7 , wherein said spasmodic disorder is renal colic crisis.10. Method for manufacturing a composition according to claim 1 , comprising the following steps:a) preparing an effervescent mixture comprising an association of at least one organic acid and/or at least ...

Подробнее
Номер записи: 57
17-03-2022 дата публикации

EXPANDABLE MICROCAPSULE

Номер: US20220079885A1
Автор: WANG TZU PIN
Принадлежит:

An expandable microcapsule, which includes a core layer consisting of 300 parts by weight of foaming agent, 250 parts by weight of polymer water-absorbing material and 60 parts by weight of core layer lubricant, wherein the foaming agent has characteristics of reacting with water to generate gas; and a coating layer covering the surface of the core layer to form a granular structure, wherein the coating layer is consisting of 10% to 40% by weight of edible water-absorbent colloid, 5% to 40% by weight of functional health food additives, 2% to 30% by weight of emulsifier, 4% to 15% by weight of coating layer lubricant and 5% to 40% by weight of film coating composition, and wherein the film coating composition has characteristics of resistance to gastric acid decomposition and being decomposed only in the intestinal tract. 1. An expandable microcapsule , comprising:a core layer consisting of 300 parts by weight of foaming agent, 250 parts by weight of polymer water-absorbing material and 60 parts by weight of core layer lubricant, wherein the foaming agent has characteristics of reacting with water to generate gas; anda coating layer covering the surface of the core layer to form a granular structure, wherein the coating layer is consisting of 10% to 40% by weight of edible water-absorbent colloid, 5% to 40% by weight of functional health food additives, 2% to 30% by weight of emulsifier, 4% to 15% by weight of coating layer lubricant and 5% to 40% by weight of film coating composition, and wherein the film coating composition has characteristics of resistance to gastric acid decomposition and being decomposed only in the intestinal tract.2. The expandable microcapsule according to claim 1 , wherein the foaming agent is consisting of 100 to 300 parts by weight of an acidic compound and 130 to 410 parts by weight of a basic compound claim 1 , wherein the acidic compound is composed of at least one of citric acid or tartaric acid claim 1 , and the basic compound is ...

Подробнее
Номер записи: 58
27-02-2020 дата публикации

USE OF SURFACE-REACTED CALCIUM CARBONATE FOR PREPARING SUPERSATURATED AQUEOUS SYSTEMS

Номер: US20200060281A1
Автор: Diaz Quijano Carolina, Gane Patrick A.C., Schenker Michel, Schoelkopf Joachim
Принадлежит:

The present invention relates to the use of a loaded particulate carrier comprising surface-reacted calcium carbonate loaded with an active ingredient, characterized in that the loaded particulate carrier is used for preparing an aqueous system comprising said active ingredient in dissolved form, wherein the mass concentration of dissolved active ingredient in said aqueous system corresponds to a supersaturated state. The surface-reacted calcium carbonate is a reaction product of calcium carbonate treated with COand one or more HOion donors, wherein the COis formed in situ by the HOion donors treatment and/or is supplied from an external source. 1. Use of a loaded particulate carrier comprising surface-reacted calcium carbonate loaded with an active ingredient , said active ingredient having a solubility limit in water of less than 10 g/l , measured at 20° C. and 1 bar ,characterized in that the loaded particulate carrier is used for preparing an aqueous system comprising said active ingredient in dissolved form, wherein the mass concentration of dissolved active ingredient in said aqueous system corresponds to a supersaturated state.2. The use according to claim 1 , characterized in that the surface-reacted calcium carbonate is a reaction product of ground natural calcium carbonate (GNCC) or precipitated calcium carbonate (PCC) treated with COand one or more HOion donors claim 1 , wherein the COis formed in situ by the HOion donors treatment and/or is supplied from an external source.3. The use according to claim 2 , characterized in that the one or more HOion donor is selected from a strong acid claim 2 , medium-strong acid claim 2 , weak acid claim 2 , or acidic salts thereof or mixtures thereof.4. The use according to claim 1 , characterized in that the surface-reacted calcium carbonate is obtained by a process comprising the steps of:(a) providing a suspension of natural or precipitated calcium carbonate,{'sub': a', 'a, '(b) adding at least one acid having a ...

Подробнее
Номер записи: 59
10-03-2016 дата публикации

METHODS AND COMPOSITIONS FOR DECREASING SALIVA PRODUCTION

Номер: US20160067233A1
Автор: Farber Neal M., Merello Marcelo, Ron Eyal S.
Принадлежит: NeuroHealing Pharmaceuticals, Inc.

The invention provides methods and compositions comprising an anti-cholinergic agent for decreasing saliva production and treating sialorrhea. 1. A solid composition comprising tropicamide and an excipient formulated for intra-oral administration of said tropicamide to an individual of an amount effective for decreasing saliva production in said individual.2. The solid composition according to claim 1 , wherein said composition includes an excipient selected from the group consisting of a pharmaceutically acceptable buffering agent claim 1 , a plasticizing agent claim 1 , a muco-adhesive agent claim 1 , a stabilizing agent claim 1 , a taste-masking agent claim 1 , a flavoring agent claim 1 , a breath freshening agent claim 1 , a coloring agent claim 1 , an antiseptic agent claim 1 , an inert filler agent claim 1 , a preserving agent claim 1 , nonionic polymer claim 1 , anionic polymer claim 1 , softening agent claim 1 , swelling agent claim 1 , chelating agent claim 1 , foaming agent claim 1 , and combinations thereof.3. The solid composition according to claim 2 , wherein said excipient is a muco-adhesive agent.4. The solid composition according to claim 1 , wherein said solid composition is in a dosage form selected from the group consisting of a candy composition claim 1 , film claim 1 , gum claim 1 , buccal patch claim 1 , lingual tablet claim 1 , sublingual tablet claim 1 , and fast-dissolving tablet.5. The solid composition according to claim 4 , wherein said dosage form is selected from the group consisting of a candy composition claim 4 , a film claim 4 , and a gum.6. The solid composition according to claim 5 , wherein said dosage form is a film.7. The solid composition according to claim 5 , wherein said dosage form is a candy composition.8. The solid composition according to claim 7 , wherein said candy composition is a lozenge or a lollipop.9. The solid composition according to claim 1 , wherein said tropicamide is present in said composition in an ...

Подробнее
Номер записи: 60
11-03-2021 дата публикации

Avoiding gag reflex to enable swallowing pills

Номер: US20210069097A1
Автор: Glen D. Lindbo
Принадлежит: Individual

Compositions and methods to avoid the gag reflex to enable swallowing of pills, by applying an edible coating to the pill that generates bubbles, so that the bubbles prevent direct contact of the pill with the back of the mouth, thereby avoiding the gag reflex. Preferably the coating generates bubbles from an acid-base reaction, from compressed bubbles entrapped in hard candy, or from any other manner for creating fizzing, effervescent or popping confectionary or other food products. Optionally the coating can have a strong taste, such as by being sour, to distract away from the gag reflex. Optionally, a time release envelope is provided to delay bubbling or to block atmospheric humidity.

Подробнее
Номер записи: 61
05-03-2020 дата публикации

MOUTHWASH FOR TREATING ORAL CANCERS

Номер: US20200069607A1
Автор: GONZALES Cara B.
Принадлежит: The Board of Regents of the University of Texas System

Provided are oral delivery compositions, including mouthwashes, for the delivery of thymol to a subject at risk of or having oral cancer. 1. A method of preventing or treating an oral cancer in a subject comprising administering isolated thymol or derivative thereof to an oral cavity of said subject.2. The method of claim 1 , wherein said oral cancer is a squamous cell carcinoma or adenocarcinoma.3. The method of claim 1 , wherein said subject is a non-human mammal.4. The method of claim 1 , wherein said subject is a human.5. The method of claim 4 , wherein said human subject partakes in one or more of smoking claim 4 , chewing tobacco or consuming alcoholic beverages claim 4 , such as on regular/chronic basis.6. The method of claim 1 , wherein said thymol or derivative thereof is administered in a mouthwash claim 1 , such as a mouthwash comprising one or more of a flavorant claim 1 , a preservative claim 1 , fluoride claim 1 , or an anti-bacterial/anti-fungal agent claim 1 , and/or may lack alcohol.7. (canceled)8. The method of claim 1 , wherein thymol or derivative thereof is administered at about 1 to 100 mM claim 1 , about 1-50 mM claim 1 , about 1-20 mM claim 1 , about 1-10 mM claim 1 , or about 2-5 mM.9. The method of claim 1 , wherein thymol or derivative thereof is administered more than once claim 1 , such as daily claim 1 , twice daily claim 1 , or every other day.10. (canceled)11. The method of claim 1 , wherein the subject is known to have an oral HPV infection.12. The method of claim 1 , wherein thymol or derivative thereof is injected into a tumor.13. The method of claim 1 , further comprising administering to said subject a second cancer therapy claim 1 , such as chemotherapy claim 1 , radiotherapy claim 1 , immunotherapy claim 1 , toxin therapy claim 1 , phototherapy claim 1 , cryotherapy or surgery.14. (canceled)15. The method of claim 1 , wherein one or more of cancer development claim 1 , cancer recurrence claim 1 , cancer metastasis claim 1 , ...

Подробнее
Номер записи: 62
05-06-2014 дата публикации

Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration

Номер: US20140154313A1
Автор: Counts David F., Cox Donald P., Dam Anup K., Stalhamer Michael E.
Принадлежит: STI PHARMA, LLC

The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a watersoluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours. 1. A particulate composition comprising:(a) a biologically active core, said biologically active core comprising a pharmaceutically active substance and a set of one or more drug binding polymers, wherein said pharmaceutically active substance being in reversible association with said set of one or more drug binding polymers; and(b) a coat, said coat comprising a membrane-forming polymer, said membrane-forming polymer surrounding said core, wherein said pharmaceutically active substance comprises a pharmaceutically active compound, a pharmaceutically acceptable salt of said pharmaceutically active compound or a combination thereof.2. A particulate composition comprising:(a) a biologically inert core, said biologically inert core comprising a set of one or more drug binding polymers; and(b) a coat, said coat comprising a membrane-forming polymer, said membrane-forming polymer surrounding said core.3. The particulate ...

Подробнее
Номер записи: 63
23-03-2017 дата публикации

EFFERVESCENT GARGLE TABLET AND METHOD OF USING SAME

Номер: US20170080024A1
Автор: "Lockard-OConnor Janet January", "OConnor Timothy P."
Принадлежит:

An anhydrous composition is provided. The anhydrous composition may be a tablet configured to dissolve in water, the tablet including Vitamin C (as ascorbic acid), Vitamin E (as dl-alpha-tocopheryl acetate), Magnesium (as magnesium sulfate and magnesium oxide), Zinc (as zinc sulfate), Chloride (as sodium chloride), Sodium (as sodium chloride, sodium bicarbonate and Sodium carbonate), Potassium (as potassium bicarbonate), Salt (as sodium chloride), , Chamomile (as ), Honey, and/or Stevia Leaf extract. The anhydrous composition may further comprise Citric Acid, Sorbitol, Natural flavor, Wheat Germ Oil, and/or Magnesium Oxide. 1. An effervescent tablet comprising:an effervescent agent comprising an acid and a base;from 10% by weight to 40% by weight of the acid;from 10% by weight to 40% by weight of the base;at least 15% by weight sodium chloride;from 0.25% by weight to 20% by weight honey;{'i': 'aloe vera;', 'from 0.25% by weight to 10% by weight'}from 0.25% by weight to 10% by weight chamomile;from 0.1% by weight to 5% by weight stevia leaf extract;from 0.5% by weight to 4% by weight ascorbic acid;from 2% by weight to 4.5% by weight potassium bicarbonate;from 4% by weight to 18% by weight sodium bicarbonate or sodium carbonate;from 0.1% by weight to 0.25% by weight zinc; andfrom 0.05% by weight to 0.45% by weight Vitamin E.2. The effervescent tablet of claim 1 , wherein the acid is citric acid and the base is magnesium oxide.3. The effervescent tablet of claim 1 , wherein the tablet comprises at least 1000 g of sodium chloride.4. The effervescent tablet of claim 1 , wherein the sodium chloride is at least 40% by weight.5. The effervescent tablet of claim 1 , wherein the tablet further comprises menthol. This application is a divisional of U.S. Patent Application to O'Connor et al. entitled “EFFERVESCENT GARGLE TABLET AND METHOD OF USING SAME,” Ser. No. 14/226,064 filed Mar. 26, 2014 which claims priority to U.S. Provisional Patent Application to O'Connor et al. ...

Подробнее
Номер записи: 64
23-03-2017 дата публикации

EFFERVESCENT GARGLE TABLET AND METHOD OF USING SAME

Номер: US20170080025A1
Автор: "Lockard-OConnor Janet January", "OConnor Timothy P."
Принадлежит:

An anhydrous composition is provided. The anhydrous composition may be a tablet configured to dissolve in water, the tablet including Vitamin C (as ascorbic acid), Vitamin E (as dl-alpha-tocopheryl acetate), Magnesium (as magnesium sulfate and magnesium oxide), Zinc (as zinc sulfate), Chloride (as sodium chloride), Sodium (as sodium chloride, sodium bicarbonate and Sodium carbonate), Potassium (as potassium bicarbonate), Salt (as sodium chloride), Aloe Vera, Chamomile (as matricaria recutita), Honey, and/or Stevia Leaf extract. The anhydrous composition may further comprise Citric Acid, Sorbitol, Natural flavor, Wheat Germ Oil, and/or Magnesium Oxide. 1. A method of treating an individual with a sore throat , the method comprising:disintegrating an effervescent tablet in about 120 ml of water to form a resulting composition, the effervescent tablet comprising:an effervescent agent comprising an acid and a base;from 5% by weight to 40% by weight of the acid;from 10% by weight to 70% by weight of the base; andat least 15% by weight sodium chloride; andorally administering the resulting composition to the individual.2. The method of claim 1 , wherein the orally administering the resulting composition further comprises:gargling a first half of the resulting composition for about 15 seconds;expelling the first half of the resulting solution;gargling a second half of the resulting composition for about 15 seconds; andexpelling the second half of the resulting solution. This application is a divisional of U.S. Patent Application to O'Connor et al. entitled “EFFERVESCENT GARGLE TABLET AND METHOD OF USING SAME,” Ser. No. 14/226,064 filed Mar. 26, 2014 which claims priority to U.S. Provisional Patent Application to O'Connor et al. entitled “EFFERVESCENT GARGLE TABLET AND METHOD OF USING SAME,” Ser. No. 61/805,744 filed Mar. 27, 2013, the disclosures of which are hereby incorporated entirely herein by reference.Technical FieldThe following relates generally to effervescent ...

Подробнее
Номер записи: 65
31-03-2022 дата публикации

METHOD AND COMPOSITION FOR MAKING AN ORAL SOLUBLE FILM, CONTAINING AT LEAST ONE ACTIVE AGENT

Номер: US20220096374A1
Автор: Fuisz Joseph M., Fuisz Richard C.
Принадлежит:

A method of making an oral soluble film, containing at least one active agent, includes providing a well of a predetermined size; depositing a film forming composition in the well; depositing an active agent composition in the well, the active agent composition being different than the film forming composition, the film forming composition and the active agent composition forming an admixture in the well; and drying the admixture in the well. Alternatively, the method includes providing a well of a predetermined size; depositing a film forming composition including at least one active agent in the well, the film forming composition having a viscosity below 2000 centipoise; and drying the film forming composition in the well. 1. A method of making soluble films containing at least one active agent , comprising:moving a substrate comprising a plurality of wells intermittently relative to a filler apparatus comprising a bank of feeder nozzles;depositing the film forming composition comprising at least one active agent into a plurality of the wells through each of the bank of feeder nozzles using a deposit pattern matched to a dimension of the well while the substrate is stationary relative to the filler apparatus, wherein film forming composition forms a film each of the plurality of wells without mechanical intervention; and thenmoving the wells containing the film forming composition to a dryer.2. The method according to claim 1 , further comprising drying the film forming composition in the wells in the dryer using hot air currents.3. The method according to claim 1 , further comprising forming the plurality of wells from a flat roll stock substrate prior to depositing the film forming composition claim 1 , and covering and sealing the films formed in the plurality of wells claim 1 , wherein forming the plurality of wells from the flat roll stock substrate claim 1 , depositing the film forming composition into the plurality of wells and covering and sealing the ...

Подробнее
Номер записи: 66
12-03-2020 дата публикации

IMMEDIATE RELEASE ABUSE DETERRENT TABLET

Номер: US20200078354A1
Автор: Fesharaki Shahin, Sareen Rahul, Shah Parag
Принадлежит: ALLERGAN SALES, LLC

The invention relates to an abuse deterrent immediate release tablet. 1. An immediate release solid pharmaceutical tablet comprising:i) a therapeutically effective amount of a drug that is subject to abuse, wherein the drug is selected from the group consisting of alfentanil, alimemazine, alprazolam, amphetamine, buprenorphine, butorphanol, clonazepam, codeine, cyclobenzaprine, diazepam, dihydrocodeine, dihydromorphine, dronabinol, estazolam, ezopiclone, fentanyl, flurazepam, hydrocodone, hydromorphone, lorazepam, methobarbital, methylphenidate, methadone, morphine, oxycodone, oxymorphone, phenobarbital, secobarbital, tempazepam, tramadol, triazolam, zaleplon, zopiclone, zolpidem and pharmaceutically acceptable salts thereof;ii) about 1 to about 20 weight percent of a polyethylene oxide polymer having a molecular weight of 900,000 to 7,000,000;iii) about 1 to about 20 weight percent of an effervescent agent;iv) about 5 to about 75 weight percent of a filler selected from the group consisting of lactose, starch, dextrose, sucrose, fructose, maltose, mannitol, sorbitol, kaolin, microcrystalline cellulose, powdered cellulose, dextrates, calcium sulfate, calcium phosphate, dicalcium phosphate, lactitol or any combination of the foregoing;v) about 1 to about 10 weight percent of a second nasal irritant other than the effervescent agent wherein the second nasal irritant is selected from the group consisting of sodium lauryl sulfate, poloxamer, sorbitan monoesters and glycerol monooleates; andvi) a disintegrant selected from the group consisting of corn starch, croscarmellose sodium, crospovidone, sodium starch glycolate or any combination of the foregoingwherein the tablet releases 40-90% of the drug in 30 minutes and 70-100% of the drug in 45 minutes when measured by a USP Apparatus Type 2 dissolution test at 50 rpms placed into 500 ml of purified water at 37° C.2. The tablet as defined in wherein the drug is selected from the group consisting of buprenorphine claim 1 , ...

Подробнее
Номер записи: 67
21-03-2019 дата публикации

Production method and effervescent formulations comprising cephalosporin and clavulanic acid

Номер: US20190083385A1
Автор: Mahmut Bilgic
Принадлежит: Individual

The present invention relates to the process for the preparation of the pharmaceutical formulations comprising a cephalosporin antibiotic and clavulanic acid or any pharmaceutically acceptable derivative thereof. The present invention also relates to processes for preparation of said formulations and their use in bacterial infections.

Подробнее
Номер записи: 68
26-06-2014 дата публикации

NON-MUCOADHESIVE FILM DOSAGE FORMS

Номер: US20140179653A1
Автор: Breitenbach Armin, Galfetti Paolo, Lehrke Ingo, Leichs Christian
Принадлежит:

Orally disintegrating film dosage forms for delivering active pharmaceutical agents, methods of formulating the dosage forms to retard absorption through the oral mucosa, and methods of using the dosage forms for the treatment of various medical conditions are provided. 122-. (canceled)23. A non-mucoadhesive orally disintegrating film , able to disintegrate upon contact with saliva in the buccal cavity within about sixty seconds , comprising a defined amount of an active pharmaceutical agent , or a pharmaceutically acceptable salt thereof , a hydrophilic binder and a water-soluble diluent , wherein:a) said film is characterized predominantly by gastrointestinal absorption when placed on the tongue, allowed to disintegrate, and subsequently swallowed;b) said film is bioequivalent to an immediate release tablet or capsule or orally dissolving/dispersing tablet (ODT) that comprises said active pharmaceutical agent or a pharmaceutically acceptable salt thereof in said defined amount; andc) said film comprises from about 0.05% to about 50% (w/w) of said active pharmaceutical agent, based on the total weight of the formulation.24. The film of characterized by greater than 95% gastrointestinal absorption.25. The film of comprising from about 40% to about 80% (w/w) of one or more ingredients that constitute said hydrophilic binder and water soluble diluent.26. The film of wherein said active pharmaceutical agent is selected from: donepezil hydrochloride; ondansetron base; desloratadine; olanzapine; risperidone; rivastigmine tartrate; sildenafil; vardenafil; galantamine; diclofenac potassium; buprenorphine HCl; naloxone HCl dehydrate; alprazolam; clonazepam; diazepam; lorazepam; sumatriptan; eletriptan; rizatriptan; zolmitriptan; naratriptan; almotriptan; frovatriptan; cetirizine hydrochloride; loratadine; ambroxol hydrochloride; apomorphine; ascorbic acid; betamethasone; caffeine; dextromethorphan; glimepiride; hydrocortisone; ketotifen; loperamide; meclozine; melatonin; ...

Подробнее
Номер записи: 69
20-04-2017 дата публикации

COATING AGENT FOR SOLID PREPARATION, AND FILM AND COATED SOLID PREPARATION FORMED THEREWITH

Номер: US20170105940A1
Автор: Horiuchi Yasuhide, Ohta Kotoe, Takaki Suguru
Принадлежит:

A coating agent imparts gas barrier properties to a solid preparation while keeping rapid disintegration properties of the solid preparation, and a coating formed therewith, and provides a coated solid preparation that maintains its rapid disintegration properties and gas barrier properties, and does not generate cracks in the coating under humidified conditions. The coating agent for a solid preparation contains lactose and a swelling clay, but does not contain a water-soluble polymer, wherein the weight of the swelling clay is 20 to 50% with respect to the weight of the solid content. 111.-. (canceled)12. A coating agent for a solid preparation comprising lactose and a swelling clay , but not comprising a water-soluble polymer , wherein the weight of said swelling clay is 20 to 50% with respect to the weight of the solid content.13. The coating agent according to claim 12 , wherein said swelling clay is bentonite or aluminum magnesium silicate.14. The coating agent according to claim 12 , comprising a saccharide selected from the group consisting of saccharose claim 12 , trehalose claim 12 , sorbitol claim 12 , xylitol claim 12 , maltitol claim 12 , maltose claim 12 , lactitol claim 12 , fructose claim 12 , and glucose.15. The coating agent according to claim 12 , wherein the weight of said lactose is 10 to 70% with respect to the weight of the solid content.16. The coating agent according to claim 14 , wherein the total weight of said lactose and said saccharide is 30 to 80% with respect to the weight of the solid content.17. The coating agent according to claim 14 , wherein the weight of said swelling clay:the weight of said lactose=1:0.5 to 1:4 claim 14 , and the weight of said swelling clay:the weight of said saccharide=1:0.2 to 1:4.18. A coating formed with the coating agent according to .19. The coating according to claim 18 , whose disintegration occurs in an oral cavity in less than 18 seconds.20. A coated solid preparation comprising a solid preparation ...

Подробнее
Номер записи: 70
20-04-2017 дата публикации

PHARMACEUTICAL COMPOSITION CONTAINING INDOMETACIN AND/OR ACEMETACIN

Номер: US20170105966A1
Автор: Imboden Roger, Lutz Juerg, Rothenbuhler Eric
Принадлежит:

The invention relates to a pharmaceutically active composition or pharmaceutical form of administering that contains at least one of the active ingredients indomethacin or acemetacin and optionally other adjuvants, the composition containing the active ingredient, or a mixture of the active ingredients, in micronized form, preferably mixed with at least one flavonoid derivative or a polypeptide or with a mixture of such compounds 1. A pharmaceutically effective composition consisting of:a mixture with at least one flavonoid derivative selected from the group consisting of: chalcones glycosides and dihydrochalcones glycosides, and combinations thereof; and (i) the active ingredient or a mixture of these active ingredients is/are in micronized form, whereby said micronized form has been obtained by micronization using mechanical means;', '(ii) the micronized active ingredient has a particle size distribution in the range of 0.1 μm (micron) to 100 μm (micron); and', '(iii) said active ingredient in micronized form being present in the form of microcrystals;, 'at least one of the active ingredients indomethacin and acemetacin, characterized in that'}wherein said composition is in a pharmaceutical form for oral administration.2. Composition according to claim 1 , characterized in that the micronized active ingredient or mixture of micronized active ingredients has been obtained by micronization using dry grinding claim 1 , jet milling or wet grinding.3. Composition according to claim 1 , characterized in that it is in the form of (i) tablets claim 1 , (ii) capsules claim 1 , or (iii) a liquid dosage form.4. Composition according to claim 1 , characterized in that the pharmaceutical form of oral administration is in the form of bulk powders claim 1 , pellets claim 1 , peroral tablets claim 1 , chewing tablets claim 1 , oral tablets claim 1 , dissolving tablets or effervescent tablets; filled in hard gelatin capsules or soft gelatin capsules; or a solution claim 1 , ...

Подробнее
Номер записи: 71
28-04-2016 дата публикации

HYDROGEN-GENERATING EFFERVESCENT TABLET AND METHODS THEREFOR

Номер: US20160113865A1
Автор: Kazakevitch Mikhail, LeBaron Tyler
Принадлежит: H2TAB LLC

Convenient, inexpensive and portable effervescent tablets that the consumer can add to water to generate hydrogen-rich water just prior to drinking. The effervescent tablets include a base metal and an edible acid that, within about 5-10 minutes of mixing, generate a palatable aqueous solution having about 0.8 mM to about 3 mM hydrogen and a pH of 8-10. 1. An effervescent tablet , for the generation of molecular hydrogen in water , comprising:a) a quantity of a base metal ranging from between about 5 mg and about 200 mg of the base metal;{'sup': '−7', 'b) a quantity of an edible non-hydroscopic dry organic acid ranging from between about 20 mg and about 400 mg of the organic acid, wherein the quantity of the organic acid corresponds with the quantity of the base metal, wherein stoichiometrically the limiting reactant is such that the proton concentration is lower than 1eM; and'}c) a quantity of an edible binding excipient material ranging from between about 200 mg and about 800 mg of the binding excipient material; whereind) when diluted in a quantity of water to a mixture including between about 200 ml of water and about 2 liters of water, the effervescent tablet yields a hydrogen concentration between about 0.8 mM hydrogen and about 3 mM hydrogen and a final pH of the mixture of between about 8 and about 10.2. The effervescent tablet according to claim 1 , wherein:a) the quantity of base metal is between 30 mg and 60 mg of the base metal.3. The effervescent tablet according to claim 1 , wherein:a) the base metal is an active non-ionic metallic metal.4. The effervescent tablet according to claim 1 , wherein:a) the base metal is selected from the group consisting of strontium, calcium, magnesium, aluminum, manganese, zinc, iron and mixtures thereof.5. The effervescent tablet according to claim 1 , wherein:a) the edible dry organic acid is selected from the group consisting of an organic acid, an inorganic acid, a Lewis acid and mixtures thereof.6. The effervescent ...

Подробнее
Номер записи: 72
09-06-2022 дата публикации

SOLID PREPARATION, METHOD FOR PRODUCING SOLID PREPARATION, AND METHOD FOR GENERATING HYDROGEN

Номер: US20220175826A1
Автор: KOBAYASHI Hikaru, Kobayashi Yuki
Принадлежит:

One solid preparation of the present invention mainly includes silicon fine particles, and has a capability of generating hydrogen. In addition, one specific example of the solid preparation mainly includes silicon fine particles having a crystallite diameter principally of 1 nm or more and 100 nm or less, and exhibits a capability of generating hydrogen in an amount of 3 ml/g or more when brought into contact with a water-containing liquid having a pH value of 7 or more. In this solid preparation, hydrogen is generated when the silicon fine particles are brought into contact with a water-containing liquid having a pH value of 7 or more. Therefore, taking advantage of the characteristics of the solid preparation, generation of hydrogen is promoted in, for example, a gastrointestinal tract where the pH value is 7 or more due to secretion of pancreatic fluid after passage through the stomach after oral ingestion. 1. A food comprising an aggregate of silicon fine particles having a silicon dioxide film having a thickness of 1.6 nm or less , wherein the aggregate has a size of 0.1 μm or more , and wherein the aggregate has a capability of generating hydrogen when the aggregate contacts a gastrointestinal tract internal fluid in a small intestine or subsequent tract , wherein the preparation is orally ingestible.2. The food according to claim 1 , further comprising an organic acid.3. The food according to claim 1 , wherein the food is a capsule preparation in which the silicon fine particles are encapsulated claim 1 , or a tablet formed so that the silicon fine particles are in a lump form.4. The food according to claim 1 , further comprising a binding agent configured to bring the silicon fine particles into a lump form for oral ingestion.5. A food additive comprising an aggregate of silicon fine particles having a silicon dioxide film having a thickness of 1.6 nm or less claim 1 , wherein the aggregate has a size of 0.1 μm or more claim 1 , and wherein the aggregate ...

Подробнее
Номер записи: 73
13-05-2021 дата публикации

Compositions for cyp450 phenotyping using saliva samples

Номер: US20210139945A1
Автор: Armin Gerhardt, Joseph McGraw
Принадлежит: Concordia University Inc

Disclosed are methods and compositions which may be used in human cytochrome P450 (CYP450) enzyme phenotyping. The methods and compositions typically utilize a mélange of substrates for different CYP450 enzymes which may be administered orally to a patient. Subsequently, the metabolites of the substrates may be detected in the patient's saliva as well as any non-metabolized substrates to calculate a metabolic ratio for any given CYP450 enzyme in order to generate a phenytopic CYP450 enzyme profile for the patient.

Подробнее
Номер записи: 74
11-05-2017 дата публикации

Effervescent compositions containing co-crystals of the acid part

Номер: US20170128359A1
Автор: Anant Paradkar, Sudhir Pagire
Принадлежит: University of Bradford

The present invention relates to effervescent compositions which are resistant to water vapour in the atmosphere and to methods of preparing such compositions. In particular, the invention relates to an effervescent composition comprising a co-crystal. The co-crystal comprises an acidic component and a basic component is separate. The co-crystal comprising the acidic component is resistant to water uptake avoiding initiating the effervescence prematurely. Upon dissolution of the co-crystal and the basic component effervescence occurs.

Подробнее
Номер записи: 75
02-05-2019 дата публикации

BONE REGENERATION PROMOTING COMPOSITION AND BONE REGENERATION PROMOTING APPARATUS

Номер: US20190125686A1
Автор: ICHIHASHI Kenichi, KAMEI Ichiro
Принадлежит:

[Problem] To provide a composition and apparatus for promoting the regeneration of bone, specifically cartilage, as well as a bone regeneration promoting method. 1. A method for promoting bone regeneration comprising a step of ingesting a composition for bone regeneration promotion comprising nanobubbles of hydrogen , and/or oxygen and nitrogen.2. The method for promoting bone regeneration according to claim 1 , further comprising one or more step(s) selected from a step for hormesis and a step for atmospheric pressure changing therapy.35.-. (canceled)6. A cartilage regeneration system comprising a composition for bone regeneration promotion comprising nanobubbles of hydrogen claim 1 , and/or oxygen and nitrogen claim 1 , an apparatus for hormesis and a device for atmospheric pressure changing therapy.7. The cartilage regeneration system according to claim 6 , wherein the apparatus for hormesis is a hormesis sheet.8. The method for promoting bone regeneration according to claim 2 , comprising a method for operation of the atmospheric pressure changing therapy claim 2 , which pressurize to 1.1-1.5 atm claim 2 , wherein a ratio of hydrogen:oxygen:nitrogen is 0.1 to 4.0:20 to 50:46 to 79.1.9. The cartilage regeneration system according to claim 6 , wherein the said device for atmospheric pressure changing therapy comprising a sealable capsule device claim 6 , comprisinga mean for supplying mixed gas of hydrogen, oxygen and nitrogen, anda mean regulating an atmospheric pressure in the capsule. The present invention relates to a composition for promoting bone regeneration and a bone regeneration promoting device, and more particularly to a composition for promoting cartilage regeneration and a cartilage regeneration promoting device.Since cartilage tissue does not have a tissue nutrition system by blood circulation, it has poor tissue repair ability, and once damaged it is difficult to repair or regenerate it. If articular cartilage repair or regeneration is not ...

Подробнее
Номер записи: 76
03-06-2021 дата публикации

Effervescent tablets that include crystalline sugar binder and methods of making the same

Номер: US20210161803A1
Автор: Carrie Kraling, Sarah Olson, Shayna JILEK
Принадлежит: Amerilab Technologies Inc

An effervescent tablet that exhibits rapid disintegration is disclosed. The effervescent tablet includes an effervescent agent that includes an acid and a base, a crystalline sugar binder selected from the group consisting of crystalline dextrose, crystalline sucrose, crystalline fructose, and combinations thereof, the crystalline sugar binder being essentially free of excipients, a sweetener that includes at least one of Stevia and Monk fruit, a flavor agent that includes a gum Arabic carrier, and optionally a lubricant derived from rice hulls (e.g., a multi-component integral lubricant).

Подробнее
Номер записи: 77
21-05-2015 дата публикации

PREPARATIONS OF EFFERVESCENT FORMULATIONS COMPRISING SECOND AND THIRD GENERATION CEPHALOSPORIN AND USES THEREOF

Номер: US20150140111A1
Автор: Bilgic Mahmut
Принадлежит:

The invention relates to effervescent pharmaceutical dosage forms including cefdinir as the active agent, and their preparation. The invention also relates to effervescent formulations including ceftibuten and/or its pharmaceutically acceptable salts, hydrates, solvates, esters, amorphous and crystal forms and/or a combination thereof. The invention also relates to pharmaceutical compositions including (Z)-3-Carboxymethyl-7-(2-(2-furyl)-2-methoxyiminoacetylamino)-3-sefem-4-carboxylic acid which is named cefuroxime axetil or any pharmaceutically acceptable derivative thereof, and the use of these compositions in the treatment of bacterial infections. Lastly, the invention relates to pharmaceutical formulations including a third generation cephalosporin together with clavulanic acid and/or derivatives thereof as the active agents. 1. A pharmaceutical formulation formulated in effervescent form comprising cefdinir as the active agent characterized in that two different taste regulating agents are used and the ratio of the first taste regulating agent having 31-90% (w/w) water solubility at 25° C. and the second taste regulating agent having 5-30% (w/w) water solubility at 25° C. is in the range of 5:1 and 1:1.2. (canceled)3. The pharmaceutical formulation according to claim 1 , wherein the first taste regulating agent used in effervescent formulations of the present invention is selected from a group comprising dextrose claim 1 , fructose claim 1 , glucose claim 1 , lactitol claim 1 , maltitol claim 1 , maltose claim 1 , sorbitol claim 1 , saccharine sodium claim 1 , sodium cyclamate claim 1 , sodium chloride claim 1 , potassium chloride claim 1 , sucrose and xylitol or combinations thereof.4. The pharmaceutical formulation according to claim 3 , wherein sodium chloride is used as the first taste regulating agent.5. The pharmaceutical formulation according to claim 1 , wherein the second taste regulating agent used in effervescent formulations of the present invention ...

Подробнее
Номер записи: 78
28-05-2015 дата публикации

PREPARATIONS OF EFFERVESCENT FORMULATIONS COMPRISING CEPHALOSPORIN AND USES THEREOF

Номер: US20150147279A1
Автор: Bilgic Mahmut
Принадлежит:

The present invention relates to a process for preparing effervescent dosage forms comprising at least one antibiotic of cephalosporin group. The present invention also relates to effervescent formulations and preparations comprising antibiotics of second generation cephalosporin. 1. A process for the preparation of a pharmaceutical composition comprising at least one cephalosporin antibiotic in the effervescent form , said method comprising a wet granulation method using a granulation solution comprising 5-25% of water by weight and a pharmaceutically acceptable organic solvent as granulation solvent.2. A process according to claim 1 , wherein said granulation solution comprises 8-20% of water and a pharmaceutically acceptable organic solvent is used.34-. (canceled)5. A process according to claim 1 , wherein said organic solvent is an alcohol claim 1 , and said alcohol is selected from the group consisting of methanol claim 1 , ethanol claim 1 , prophanol claim 1 , cethyl alcohol claim 1 , ethylene glycol claim 1 , glycerin claim 1 , and combinations thereof.6. A process according to claim 5 , wherein ethanol is used as an organic solvent.7. A process according to claim 6 , wherein said granulation solution comprises a binder in addition to water and ethanol.8. A process according to claim 6 , wherein the ratio of water to ethanol used in the granulation solution is in the range of 1:1 and 1:15 by weight.910-. (canceled)11. A process for preparing a pharmaceutical composition according to claim 1 , wherein said process comprises the following steps:a. obtaining a granulation solution by mixing a granulation solvent with 30-60% of total amount of a binder;b. sieving an effervescent acid and base;c. sieving a taste regulator;d. loading the effervescent acid, effervescent base obtained in step b, taste regulator obtained in step c, and 40-70% of the total amount of binder into the fluidized bed dryer and granulating them by the granulation solution prepared in step a; ...

Подробнее
Номер записи: 79
24-05-2018 дата публикации

PHARMACEUTICAL COMPOSITION

Номер: US20180140543A1
Автор: CHIANG Ching-Hua, CHUANG Er-Yuan, Lin Po-Yen, Sung Hsing-Wen
Принадлежит:

The present invention provides a pharmaceutical composition, comprising a hydrophobic active ingredient; a surfactant having hydrophobic end and hydrophilic end; an acidic component; and an effervescent ingredient. The acidic component reacts with the effervescent ingredient in water to generate carbon dioxide. The hydrophobic ends of the surfactant surround carbon dioxide. The hydrophobic active ingredient attaches to the hydrophobic ends of the surfactant. 2. The pharmaceutical composition according to claim 1 , wherein the surfactant comprises anionic surfactants claim 1 , cation surfactants claim 1 , amphiprotic surfactants claim 1 , or nonionic surfactants.3. The pharmaceutical composition according to claim 1 , wherein the surfactant comprises sodium lauryl sulfate claim 1 , polyethylene glycol sorbitan monooleate claim 1 , or sodium dodecyl benzene sulfonate.4. The pharmaceutical composition according to claim 1 , wherein the effervescent ingredient comprises carbonates or bicarbonates.5. The pharmaceutical composition according to claim 1 , wherein the acidic component comprises diethylenetriaminepentaacetic dianhydride (DTPA anhydride) claim 1 , organic acid anhydride claim 1 , citric acid claim 1 , or decanoic acid.6. The pharmaceutical composition according to claim 1 , wherein the hydrophobic active ingredient comprises curcumin claim 1 , paclitaxel claim 1 , or doxorubicin.7. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is in form of a tablet or a capsule.8. The pharmaceutical composition according to further comprising an enteric coating enveloping the tablet or capsule.9. The pharmaceutical composition according to claim 8 , wherein the enteric coating comprises a methacrylic acid copolymer claim 8 , hypromellose phthalate claim 8 , hydroxypropyl cellulose acetate claim 8 , hydroxypropyl cellulose succinate claim 8 , or carboxy methyl ethyl cellulose. The present invention relates to a pharmaceutical ...

Подробнее
Номер записи: 80
16-05-2019 дата публикации

METHOD AND COMPOSITION FOR MAKING AN ORAL SOLUBLE FILM, CONTAINING AT LEAST ONE ACTIVE AGENT

Номер: US20190142743A1
Автор: Fuisz Joseph M., Fuisz Richard C.
Принадлежит:

A method of making an oral soluble film, containing at least one active agent, includes providing a well of a predetermined size; depositing a film forming composition in the well; depositing an active agent composition in the well, the active agent composition being different than the film forming composition, the film forming composition and the active agent composition forming an admixture in the well; and drying the admixture in the well. Alternatively, the method includes providing a well of a predetermined size; depositing a film forming composition including at least one active agent in the well, the film forming composition having a viscosity below 2000 centipoise; and drying the film forming composition in the well. 1. A method of making an oral soluble film containing at least one active agent , comprising:continuously stirring a suspension of a film forming composition and particulates of at least one active agent in a tank;depositing the suspension of the film forming composition and the particulates of the at least one active agent separately into each of a plurality of wells while continuously stirring the suspension in the tank, the suspension of the film forming composition and the particulates of the at least one active agent having a yield stress of less than 30 Pa and forming a contact angle with the well of less than 90°, wherein the suspension of the film forming composition and has a viscosity below 600 centipoise; anddrying the film.2. The method according to claim 1 , wherein the suspension of the film forming composition and at least one active agent has a yield stress of less than 15 pa.3. The method according to claim 1 , wherein the suspension of the film forming composition and at least one active agent has a viscosity below 300 centipoise.4. The method according to claim 1 , wherein drying the film comprises drying the film using infrared drying.5. The method according to claim 1 , wherein drying the film comprises drying the film using ...

Подробнее
Номер записи: 81
21-08-2014 дата публикации

EFFERVESCENT COMPOSITIONS CONTAINING N-ACETYLCYSTEINE

Номер: US20140234228A1
Автор: ARDALAN Shahbaz S., GRANATA Gabriele, STROPPOLO Federico
Принадлежит: ALPEX PHARMA S.A.

Effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine and a method of treating acetaminophen poisoning with effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine are described. 1. An effervescent composition comprising at least 50% w/w of N-acetylcysteine , at least 20% w/w of a carbonate or bicarbonate salt and a mixture of pharmaceutically acceptable excipients comprising a sweetener , a flavor , and a diluent.2. The effervescent composition according to wherein the amount of N-acetylcysteine is from 50% to 80% w/w.3. The effervescent composition according to wherein the amount of N-acetylcysteine is from 50% to 60% w/w.4. The effervescent composition according to wherein the amount of N-acetylcysteine is about 54-55% w/w.5. The effervescent composition according to wherein the carbonate or bicarbonate salt is selected from the group consisting of sodium bicarbonate claim 1 , sodium carbonate claim 1 , potassium bicarbonate claim 1 , potassium carbonate claim 1 , sodium sesquicarbonate claim 1 , sodium glycine carbonate.6. The effervescent composition according to wherein the bicarbonate salt is sodium bicarbonate.7. The effervescent composition according to wherein the amount of carbonate or bicarbonate salt is from 20% to 45% w/w.8. The effervescent composition according to wherein the amount of carbonate or bicarbonate salt is from 30% to 35% w/w.9. The effervescent composition according to wherein the sweetener is selected from the group consisting of sugars and artificial sweeteners.10. The effervescent composition according to wherein the artificial sweetener is selected from the group consisting of sodium saccharin claim 9 , acesulfame potassium claim 9 , cyclamates claim 9 , sucralose.11. The effervescent composition according to wherein the artificial sweetener is sucralose.12. The effervescent composition according to wherein the diluent is selected from the group consisting of polyols claim ...

Подробнее
Номер записи: 82
23-05-2019 дата публикации

REDUCED FOAMING VACCINE COMPOSITIONS

Номер: US20190151451A1
Автор: Genin Noel Yves Henri Jean
Принадлежит:

The present invention relates to novel stable compressed vaccine composition composing at least one anhydrous antigenic component comprising a stabilizer susceptible to foaming when the composition is mixed with liquid diluent; and an effective amount of a sugar alcohol. 121-. (canceled)22. A method of making a solid vaccine composition having reduced foaming when mixed with a liquid diluent , the method comprises mixing an effective amount of a foam controlling agent with at least one anhydrous antigenic component , a stabilizer , and an effervescent agent;wherein the foam controlling agent is a sugar alcohol, wherein the effective amount of sugar alcohol is about 15% to 40% by weight of the solid vaccine composition, andupon adding a diluent to the solid vaccine composition, the effervescent agent reacts to form gas in situ, and foam resulting from the gas is reduced.23. The method according to claim 22 , wherein the method further comprises:compressing the solid vaccine composition to form a compressed vaccine composition.24. The method according to claim 22 , wherein the at least one anhydrous antigenic component is lyophilized or dried.25. The method according to claim 22 , wherein the stabilizer comprises one or more amino acid or salts thereof claim 22 , protein or salts thereof claim 22 , albumin claim 22 , gelatin claim 22 , or combinations thereof.26. The method according to claim 22 , wherein the at least one anhydrous antigenic component is newcastle disease virus claim 22 , infectious bronchitis virus claim 22 , fowl pox virus claim 22 , avian encephalomyelitis virus claim 22 , marek's disease virus claim 22 , trichophyton verrucosum claim 22 , avian paramyxovirus claim 22 , mycobacterium paratuberculosis claim 22 , meleagrid herpesvirus claim 22 , orf virus claim 22 , or sheep pox virus.27. The method according to claim 22 , wherein the at least one anhydrous antigenic component is newcastle disease virus or infectious bronchitis virus.28. The method ...

Подробнее
Номер записи: 83
14-05-2020 дата публикации

Pharmaceutical Composition for Oral Delivery of Hydrophobic Small Molecule Drug and Hydrophilic Small Molecule Drug Concurrently

Номер: US20200146973A1
Автор: CHEN Kuan-Hung, Lin Po-Yen, Sung Hsing-Wen
Принадлежит:

A pharmaceutical composition for oral delivery of hydrophobic small molecule drug and hydrophilic small molecule drug concurrently is provided. The pharmaceutical composition includes an enteric layer and a drug layer, in which the drug layer is encapsulated in the enteric layer. The drug layer includes a therapeutically effective amount of a hydrophobic small molecule drug, a therapeutically effective amount of a hydrophilic small molecule drug, a lipophilic solvent, an acidic compound and an effervescent ingredient. 1. A pharmaceutical composition for oral delivery of hydrophobic small molecule drug and hydrophilic small molecule drug concurrently , comprising:an enteric layer; and a therapeutically effective amount of a hydrophobic small molecule drug, wherein a molar mass of the hydrophobic small molecule drug is less than 1000 g/mol;', 'a therapeutically effective amount of a hydrophilic small molecule drug, wherein a molar mass of the hydrophilic small molecule drug is less than 1000 g/mol;', 'a lipophilic solvent for dissolving the hydrophobic small molecule drug;', 'an acidic compound; and', 'an effervescent ingredient generating carbon dioxide bubbles when the acidic compound is dissolved in intestinal fluid to form an acidic environment;', 'wherein lipophilic tails of bile salts carry the hydrophobic small molecule drug dissolved in the lipophilic solvent to incorporate into a nanofilm around each of the carbon dioxide bubble to form a monolayer system, then each of the carbon dioxide bubble expands and approaches an air-liquid interface in a lumen, the monolayer system transforms into a double-layer nano-assembly having an inner layer and an outer layer, the hydrophilic small molecule drug is embedded in a gap formed between the inner layer and the outer layer of the double-layer nano-assembly, and lipid oil drops containing the hydrophobic small molecule drug are formed when the carbon dioxide bubbles burst at the air-liquid interface in the lumen., 'a ...

Подробнее
Номер записи: 84
14-05-2020 дата публикации

TASTE-MASKED PHARMACEUTICAL COMPOSITIONS

Номер: US20200146978A1
Автор: Venkatesh Gopi M.
Принадлежит:

There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity in about 60 seconds forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active) applied with a taste-masking membrane comprising a combination of water-insoluble and gastrosoluble polymers release not less than about 60% of the dose is in the stomach in about 30 minutes, thus maximizing the probability of achieving bioequivalence to the reference IR product having rapid onset of action (short Tmax). A process for preparing such compositions for oral administration using conventional fluid-bed equipment and rotary tablet press is also disclosed. 1. A pharmaceutical composition comprising: (a) a drug-containing core particle; and', '(b) a taste-masking membrane disposed on said drug-containing core particle comprising a combination of a water-insoluble polymer and a gastrosoluble polymer, wherein the ratio of the water-insoluble polymer to the gastrosoluble polymer is in the range of from about 95/5 to about 50/50; and, '(1) a plurality of taste-masked particles, wherein each taste-masked particle comprises(2) a plurality of rapidly-dispersing microgranules comprising (i) a disintegrant and (ii) a sugar alcohol or a saccharide or a combination thereof, wherein each of said disintegrant and sugar alcohol or saccharide is present in the form of particles having an average particle diameter of not more than about 30 μm.2. The pharmaceutical composition of claim 1 , wherein the rapidly-dispersing microgranules have an average particle size of not more than about 400 μm.3. The pharmaceutical composition of claim 1 , wherein the pharmaceutical ...

Подробнее
Номер записи: 85
28-08-2014 дата публикации

BODY CAVITY FOAMS

Номер: US20140241998A1
Автор: Besonov Alex, Eini Meir, Friedman Doron, Tamarkin Dov
Принадлежит: Foamix Ltd.

The invention relates to an alcohol-free cosmetic or therapeutic foam carrier comprising water, a hydrophobic organic carrier, a foam adjuvant agent, a surface-active agent and a gelling agent. The cosmetic or therapeutic foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable for inclusion of both water-soluble and oil soluble therapeutic and cosmetic agents. 1i) about 0.1% to about 5% by weight of the carrier of a surface-active agent;ii) about 2% to about 75% by weight of the carrier of an organic solvent selected from the group consisting of an emollient, a polar solvent, an oil, and mixtures thereof;iii) about 0.01% to about 5% by weight of the carrier of at least one polymeric agent selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent, and a phase change agent; andiv) water;. A foamable composition comprising a carrier and a liquefied or a compressed gas propellant, the carrier comprising: This application is a continuation of and claims benefit of priority under 35 U.S.C. §120 to U.S. application Ser. No. 13/786,902, filed Mar. 6, 2013, which is a continuation of and claims the benefit of priority to U.S. application Ser. No. 11/116,761, filed Apr. 28, 2005, which 1) is a continuation-in-part application of co-pending International Patent Application No. IB03/005527, filed Oct. 24, 2003, which claims the benefit of priority under 35 U.S.C. §119(e) to U.S. Provisional Application Ser. No. 60/429,546, filed Nov. 29, 2002, and claims the benefit of priority under 35 U.S.C. §119(a) to Israeli Patent Application No. 152486, filed Oct. 25, 2002; 2) is a continuation-in-part application of co-pending U.S. patent application Ser. No. 10/911,367, filed Aug. 4, 2004, which claims the benefit of priority under 35 U.S.C. §119(e) to U.S. Patent Application Ser. No. 60/492,385, filed Aug. 4, 2003; and 3) claims the benefit of priority under 35 U.S.C. § ...

Подробнее
Номер записи: 86
21-05-2020 дата публикации

Oral Medicine Delivery Capsule

Номер: US20200155466A1
Автор: Houtz, II Don S.
Принадлежит:

An improved oral medicine delivery capsule may feature a gelled medicine contained within a carrier capsule designed to maintain its position in the oral cavity of a patient. A port covered with a mesh or other osmotic material allows the medicine to leach through to the oral tissues. Construction may be any known or later developed formulation which balances the need to contain and control the flow of medicine with durability in the oral cavity. 1. An oral medicine delivery capsule comprising:a capsule wall defining an interior volume and having an opening within part of the capsule wall;an osmotic material residing proximate said opening; anda medicine containing compound contained within the internal volume;wherein the oral medicine delivery pouch will leach medicine through the osmoticmaterial to provide a time-released dosage of said medicine.2. The oral medicine delivery capsule of claim 1 , the osmotic material being surgical mesh.3. The oral medicine delivery capsule of claim 1 , the osmotic material being embedded in the capsule wall about the opening.4. The oral medicine delivery capsule of claim 1 , the osmotic material being fastened to the capsule wall.5. The oral delivery capsule of claim 1 , the capsule wall being made from a material selected form the group of materials consisting of: gelatin claim 1 , hypromellose claim 1 , and pullulan.6. The oral delivery capsule of claim 1 , the medicine containing compound being a colloidal gel carrier infused with medicine. This Application claims priority as a non-provisional perfection of U.S. App. No. 62/770,607, filed Nov. 21, 2019 and incorporates the same by reference in its entirety herein.The present invention relates to the field of medicine and more particularly relates to a capsule for targeted delivery of medicines to the oral cavity.The delivery of medicine to the body is accomplished by two simple concepts: either apply the medicine to the afflicted area or apply it at some other location so that ...

Подробнее
Номер записи: 87
11-09-2014 дата публикации

METHOD AND APPARATUS FOR DIFFERENTIATING ORAL POUCH PRODUCTS

Номер: US20140255452A1
Автор: Armstrong Stephen Taylor, Reddick Edwin Matthew
Принадлежит: NICONOVUM USA, INC.

A nicotine-containing pharmaceutical product configured for insertion into the mouth of a user of that product is provided. The product can have an outer water-permeable pouch, a nicotine-containing pharmaceutical composition situated within the outer water-permeable pouch, and product identifying information relating to the nicotine-containing pharmaceutical composition. The information can be presented such that a user of the product can discern the identifying information by visually inspecting the product and thereby differentiate or identify certain nicotine-containing pharmaceutical products. The product identifying can be, for example, printed, imprinted or dyed on the outer water-permeable pouch, positioned within the outer water-permeable pouch, or attached to the outer water-permeable pouch. The product identifying information can identify product brand, a company name, a corporate logo or brand, marketing messages, product strength, active ingredient, product manufacture date, product expiration date, product flavor, product pharmaceutical release profile, weight, product code, other product differentiating markings, and combinations thereof.

Подробнее
Номер записи: 88
11-09-2014 дата публикации

LOW MELTING PROPIONIC ACID DERIVATIVE PARTICLES FOR USE IN ORAL DOSAGE FORMS

Номер: US20140256810A1
Автор: Bagchi Saumitra, Vuppala Murali K.
Принадлежит: McNeil-PPC, Inc.

Low melting propionic acid derivative particles that are free flowing and have significantly reduced or eliminated throat burn are disclosed. A method of manufacturing the low melting propionic acid derivative particles; dosage forms containing the low melting propionic acid derivative particles; methods of manufacturing the dosage forms; and methods of treatment using the dosage forms are also disclosed.

Подробнее
Номер записи: 89
22-06-2017 дата публикации

RINSE-OFF CHEMICAL MOUSSE CONTAINING BENZOYL PEROXIDE

Номер: US20170172972A1
Автор: Buge Jean-Christophe, NADAU-FOURCADE Karine
Принадлежит:

A composition is described for a topical application, in the form of a rinse-off mousse, including no or only a small quantity of foaming surfactants. The composition can include a medium that is cosmetically or pharmaceutically compatible with a topical application, and benzoyl peroxide. The composition can also include at least one intermediate composition, at least one gas-generating agent, at least one agent activating the at least one gas-generating agent, and benzoyl peroxide. A kit or a single container with a plurality of compartments including this composition is also described. 1. A composition comprising benzoyl peroxide , wherein the composition is formulated as a rinse-off topical application in the form of a foam , comprising:at least one intermediate composition,at least one gas-generating agent,at least one agent that activates the at least one gas-generating agent, andbenzoyl peroxide.2. The composition as defined by claim 1 , wherein the composition comprises:at least one intermediate composition A that comprises the at least one agent that activates the at least one gas-generating agent,at least one intermediate composition B that comprises the at least one gas-generating agent, andbenzoyl peroxide present in at least one of the at least one intermediate composition A and the at least one intermediate composition B.3. The composition as defined by claim 1 , wherein the benzoyl peroxide is present in the at least one intermediate composition A.4. The composition as defined by claim 1 , wherein the composition is self-foaming.5. The composition as defined by claim 1 , wherein the composition does not comprise any foaming surfactants or claim 1 , if it comprises such surfactants claim 1 , they are present in an amount less than or equal to 1% by weight claim 1 , with respect to the weight of the total composition.6. The composition as defined by claim 1 , wherein the at least one gas generated from the at least one gas-generating agent is carbon ...

Подробнее
Номер записи: 90
18-09-2014 дата публикации

Manufacturing Process for Effervescent Dosage Forms

Номер: US20140271492A1
Автор: Tammy BARTLEY
Принадлежит: MYLAN INC

Methods of manufacturing effervescent dosage forms. Methods of manufacturing an effervescent tablet using a dry, direct compression process are disclosed. The methods do not result in the sticking of the mixture to be tableted to the punches during production.

Подробнее
Номер записи: 91
18-09-2014 дата публикации

(Trimethoxyphenylamino) Pyrimidinyl Formulations

Номер: US20140271493A1
Автор: ALHUSBAN Farhan Abdul Karim, GABBOTT Ian Paul, GURURAJAN Bindhumadhavan, SIEVWRIGHT Dawn, SIMPSON David Bradley Brook
Принадлежит: Rigel Pharmaceuticals, Inc.

There are provided pharmaceutical compositions comprising greater than 15% w/w of a compound of Formula (I) as defined herein and/or hydrate thereof and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them. 19-. (canceled)11. The method according to wherein each X in the compound of Formula (I) represents a sodium cation (Na).12. The method according to wherein the compound of Formula (I) is in the form of a hexahydrate.14. The method according to wherein each X in the compound of Formula (I) represents a sodium cation (Na).15. The method according to wherein the compound of Formula (I) is in the form of a hexahydrate.17. The method according to wherein each X in the compound of Formula (I) represents a sodium cation (Na).18. The method according to wherein the compound of Formula (I) is in the form of a hexahydrate.20. The method according to wherein each X in the compound of Formula (II) represents a sodium cation (Na).21. The method according to wherein the compound of Formula (II) is in the form of a hexahydrate.23. The method according to wherein each X in the compound of Formula (II) represents a sodium cation (Na).24. The method according to wherein the compound of Formula (II) is in the form of a hexahydrate.26. The method according to wherein each X in the compound of Formula (II) represents a sodium cation (Na).27. The method according to wherein the compound of Formula (II) is in the form of a hexahydrate.29. The method according to wherein each X in the compound of Formula (I) represents a sodium cation (Na).30. The method according to wherein the compound of Formula (I) is in the form of a hexahydrate.32. The method according to wherein each X in the compound of Formula (II) represents a sodium cation (Na).33. The method according to wherein the compound of Formula (II) is in the form of ...

Подробнее
Номер записи: 92
18-09-2014 дата публикации

Abuse Deterrent Solid Dosage Form for Immediate Release with Functional Score

Номер: US20140271849A1
Автор: David W. BOGAN, Eric A. Burge, Jae Han Park, Siva N. Raman, Sunil K. Battu
Принадлежит: Mallinckrodt LLC

The present disclosure provides an immediate release, abuse deterrent pharmaceutical solid dosage form comprising at least one functional score. In particular, the immediate release, abuse deterrent solid dosage form comprises at least one low molecular weight hydrophilic polymer, at least one high molecular weight hydrophilic polymer, and an effervescent system.

Подробнее
Номер записи: 93
04-06-2020 дата публикации

EFFERVESCENT TABLETS THAT INCLUDE CRYSTALLINE SUGAR BINDER AND METHODS OF MAKING THE SAME

Номер: US20200170935A1
Автор: Jilek Shayna, Kraling Carrie, Olson Sarah
Принадлежит: Amerilab Technologies, Inc.

An effervescent tablet that exhibits rapid disintegration is disclosed. The effervescent tablet includes an effervescent agent that includes an acid and a base, a crystalline sugar binder selected from the group consisting of crystalline dextrose, crystalline sucrose, crystalline fructose, and combinations thereof, the crystalline sugar binder being essentially free of excipients, a sweetener that includes at least one of Stevia and Monk fruit, a flavor agent that includes a gum Arabic carrier, and optionally a lubricant derived from rice hulls (e.g., a multi-component integral lubricant). 1. An effervescent tablet comprising:an effervescent agent comprising an acid and a base;a sweetener comprising Stevia, Monk fruit, or a combination thereof;a first crystalline sugar binder selected from the group consisting of crystalline dextrose, crystalline sucrose, crystalline fructose, and combinations thereof, the crystalline sugar binder being essentially free of excipients; anda flavor agent comprising gum Arabic,the effervescent tablet having a weight of at least 4 grams and a hardness of at least 5 kiloponds and exhibiting a disintegration time of no greater than 4 minutes and 20 seconds when tested according to the Disintegration Time Test Method.2. The effervescent tablet of claim 1 , wherein the crystalline sugar binder comprises crystalline dextrose monohydrate.3. The effervescent tablet of claim 1 , wherein the crystalline sugar binder comprises crystalline dextrose monohydrate and crystalline fructose.4. The effervescent tablet of claim 1 , wherein the tablet disintegrates in 25° C. water in no greater than 3.5 minutes.5. The effervescent tablet of comprisingat least 20% by weight of the effervescent agent; andfrom 20% by weight to 55% by weight of the crystalline sugar binder.6. The effervescent tablet of comprising from 0.4% by weight to 2% by weight of the sweetener.7. The effervescent tablet of comprisingat least 20% by weight of the effervescent agent; ...

Подробнее
Номер записи: 94
04-06-2020 дата публикации

RAPIDLY DISSINTEGRATING EFFERVESCENT TABLETS AND METHODS OF MAKING THE SAME

Номер: US20200170936A1
Автор: Kraling Carrie, Olson Sarah
Принадлежит: Amerilab Technologies, Inc.

An effervescent tablet that exhibits rapid disintegration is disclosed. The effervescent tablet includes an effervescent agent that includes an acid and a base, a directly compressible sugar binder, a sweetener that includes at least one of Stevia and Monk fruit, a flavor agent that includes a gum Arabic carrier, and a lubricant derived from rice hulls. 1. An effervescent tablet comprising:an effervescent agent comprising an acid and a base;a sweetener comprising Stevia, Monk fruit, or a combination thereof;a first directly compressible sugar binder;a flavor agent comprising gum Arabic; anda lubricant derived from rice hulls,the effervescent tablet having a weight of at least 4 grams and a hardness of at least 5 kiloponds, and exhibiting a disintegration time of no greater than 4 minutes and 20 seconds when tested according to the Disintegration Time Test Method.2. The effervescent tablet of comprising at least 1.5% by weight of a flavor agent comprising gum Arabic.3. The effervescent tablet of comprising at least 2% by weight of a flavor agent comprising gum Arabic.4. The effervescent tablet of claim 1 , wherein the tablet is free of flavor agents that are free of gum Arabic.5. The effervescent tablet of claim 1 , wherein the lubricant is a multi-component integral lubricant that comprises rice hull particles claim 1 , gum Arabic claim 1 , sunflower oil claim 1 , and at least one extract of rice.6. The effervescent tablet of claim 1 , wherein the directly compressible sugar binder is selected from the group consisting of directly compressible dextrose claim 1 , directly compressible sucrose claim 1 , and combinations.7. The effervescent tablet of claim 1 , wherein the directly compressible sugar binder comprises dextrose.8. The effervescent tablet of claim 1 , wherein the directly compressible sugar binder comprises a mixture of dextrose and a polysaccharide.9. The effervescent tablet of claim 1 , wherein the effervescent tablet disintegrates in 25° C. water in no ...

Подробнее
Номер записи: 95
18-09-2014 дата публикации

Method for Producing and Monitoring Oral Active Ingredient Films

Номер: US20140272099A1
Автор: BRAUN Sebastian, Breitenbach Armin, Schliephacke Ralf
Принадлежит:

Method for producing and monitoring oral active ingredient films with a base to which a solution containing at least one active ingredient is applied, the method comprising the steps: • metering and mixing the base formulation, • coating the base formulation onto a substrate, so that a strip results • if necessary, drying the base formulation strip coated on the substrate • printing a colorant solution containing at least one active ingredient onto the upper side of the base formulation strip according to the flexographic printing method, • drying the base formulation strip coated on the substrate together with the printed active ingredient solution, • penetrating the base formulation strip coated on the substrate together with the printed active ingredient solution from the upper and/or lower side by means of radiation from a radiation source, • measuring the transmission of the penetrating radiation by means of at least one reception unit on the opposite side of the base formulation strip coated on the substrate together with the printed active ingredient solution. 1. A method for producing and monitoring oral dissolvable films comprising a base whereto a solution comprising at least one active compound is applied , said method comprising the steps ofdosing and mixing the base formulation,coating the base formulation onto a support to form a web,optionally drying the support-coated base formulation web,printing a dye solution comprising at least one active compound onto the upper side of the base formulation web by the flexographic printing process,drying the support-coated base formulation web along with the printed active compound solution,passing radiation from a radiation source from the upper and/or lower side through the support-coated base formulation web along with the printed active compound solution,measuring the transmission of the transmitted radiation using at least one receiving unit on the opposite side of the support-coated base formulation web ...

Подробнее
Номер записи: 96
15-07-2021 дата публикации

Capsule device for delivery of active agent to gastrointestinal tract

Номер: US20210213263A1
Автор: Christopher A. Rhodes, Jose Casillas
Принадлежит: Baywind Bioventures

Various embodiments of an oral delivery capsule device for delivering an active agent to a part of a gastrointestinal (GI) tract of a subject are described. The capsule device may include a capsule body configured to travel along the GI tract. The capsule device may include a reservoir configured to contain an active agent for delivery to the GI tract of the subject. The oral delivery capsule device may include an actuation feature configured to provide a delivery force thereby causing the dispensing of the active agent. The oral delivery capsule device may include an actuation control feature configured to prevent actuation of the actuation feature under a first condition and allow actuation under a second condition. Related systems and methods are also described.

Подробнее
Номер записи: 97
05-07-2018 дата публикации

OPTIMIZED PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF INFLAMMATORY CONDITIONS OF THE ESOPHAGUS

Номер: US20180185277A1
Автор: Greinwald Roland, MUELLER Ralph, Proels Markus, Wilhelm Rudolf
Принадлежит: DR. FALK PHARMA GMBH

Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis. 1. An orodispersible effervescent tablet containing:a. 0.25 mg to 5 mg of budesonide;b. a salt of at least one pharmacologically acceptable acid that, in an aqueous environment, can release a gas with a further acid; and 'wherein the effervescent tablet has a mass of 100 mg to 200 mg.', 'c. a pharmaceutically acceptable weak acid or salt thereof that decreases the pH value in an aqueous solution;'}2. The orodispersible effervescent tablet of claim 1 , wherein said tablet comprises a lingual effervescent tablet formulated for direct administration to the oral cavity.3. The orodispersible effervescent tablet of claim 2 , wherein said lingual effervescent tablet further comprises a sweetener other than sucrose.4. The orodispersible effervescent tablet of claim 3 , wherein said sweetener other than sucrose is sucralose.5. The orodispersible effervescent tablet of claim 4 , wherein said tablet further contains 0.1 to 1.0% sucralose.6. The orodispersible effervescent tablet of claim 2 , wherein said salt of at least one pharmacologically acceptable acid that can release a gas with a further acid is a salt of carbonic acid.7. The orodispersible effervescent tablet of claim 6 , wherein said salt of carbonic acid is selected from the group consisting of carbonates and hydrogen carbonates.8. The orodispersible effervescent tablet of claim 6 , wherein said salt of carbonic acid ...

Подробнее
Номер записи: 98
06-07-2017 дата публикации

METHOD OF PREPARING A PHARMACEUTICAL COMPOSITION

Номер: US20170189329A1
Автор: HANSEN WILLIAM F., SCHULTZ DAVID W., SIMONS JOHN K., Stein Stephen W.
Принадлежит: 3M INNOVATIVE PROPERTIES COMPANY

The present disclosure provides a method of preparing a pharmaceutical composition. The method includes transferring a predetermined quantity of an excipient mixture from a second vessel to a first vessel. The excipient mixture transferred from the second vessel includes a liquid-state second quantity of a hydrofluoroalkane propellant and a first solubilized excipient comprising a low-molecular weight poly(ethylene oxide) polymer. The method further includes contacting at least one pharmaceutically-active compound with the excipient mixture under conditions that facilitate forming an intermixture comprising the propellant, the polymer, and the compound. Before transferring the excipient mixture, the first vessel contains a vapor-phase first quantity of the hydrofluoroalkane propellant and an effective amount of the at least one pharmaceutically-active compound. 1. A method , comprising: wherein the excipient mixture transferred from the second vessel comprises a liquid-state second quantity of a hydrofluoroalkane propellant and a first solubilized excipient;', 'wherein the first solubilized excipient comprises a low-molecular weight poly(ethylene oxide) polymer;', 'wherein, before transferring the excipient mixture, the first vessel contains a vapor-phase first quantity of the hydrofluoroalkane propellant and an effective amount of at least one pharmaceutically-active compound; and, 'transferring a predetermined quantity of an excipient mixture from a second vessel to a first vessel;'}contacting the at least one compound with the excipient mixture under conditions that facilitate forming an intermixture comprising the propellant, the first solubilized excipient, and the pharmaceutically-active compound.2. The method of claim 1 , wherein forming the intermixture comprises forming a pharmaceutical composition.3. The method of claim 1 , wherein the method further comprises mixing a liquid-state third quantity of the hydrofluoroalkane propellant with the intermixture to ...

Подробнее
Номер записи: 99
20-06-2019 дата публикации

METHOD OF PREPARING A PHARMACEUTICAL COMPOSITION

Номер: US20190183784A1
Автор: HANSEN WILLIAM F., SCHULTZ DAVID W., SIMONS JOHN K., Stein Stephen W.
Принадлежит: 3M INNOVATIVE PROPERTIES COMPANY

The present disclosure provides a method of preparing a pharmaceutical composition. The method includes transferring a predetermined quantity of an excipient mixture from a second vessel to a first vessel. The excipient mixture transferred from the second vessel includes a liquid-state second quantity of a hydrofluoroalkane propellant and a first solubilized excipient comprising a low-molecular weight poly(ethylene oxide) polymer. The method further includes contacting at least one pharmaceutically-active compound with the excipient mixture under conditions that facilitate forming an intermixture comprising the propellant, the polymer, and the compound. Before transferring the excipient mixture, the first vessel contains a vapor-phase first quantity of the hydrofluoroalkane propellant and an effective amount of the at least one pharmaceutically-active compound. 1. A method , comprising: wherein the excipient mixture transferred from the second vessel comprises a liquid-state second quantity of a hydrofluoroalkane propellant and a first solubilized excipient;', 'wherein the first solubilized excipient comprises a low-molecular weight poly(ethylene oxide) polymer;', 'wherein, before transferring the excipient mixture, the first vessel contains a vapor-phase first quantity of the hydrofluoroalkane propellant and an effective amount of at least one pharmaceutically-active compound; and, 'transferring a predetermined quantity of an excipient mixture from a second vessel to a first vessel;'}contacting the at least one compound with the excipient mixture under conditions that facilitate forming an intermixture comprising the propellant, the first solubilized excipient, and the pharmaceutically-active compound.220-. (canceled) This application claims priority to U.S. Provisional Patent Application No. 62/030,350, filed Jul. 29, 2014, the disclosure of which is incorporated by reference in its entirety herein.Pressurized metered dose inhalers (MDIs) are widely used devices ...

Подробнее
Номер записи: 100